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Summary
Dry eye syndrome is a common condition, regarded as a tear film abnormality which increases 
with age and causes symptoms such as dryness, irritation and grittiness. Its occurrence is often 
related to other health conditions such as diabetes.
Current treatments deal with the management of the tear film, and the conventional and 
common approach is instillation of lubricating eye drops or tear substitutes. These topical 
treatments generally treat the symptoms but are unable to resolve the underlying causes. It is 
therefore important to investigate the development of prevention strategies, and to investigate 
potential relationships between dietary factors and signs and symptoms of dry eye syndrome. 
This thesis set out to investigate the relationships that might exist between dietary factors 
and signs and symptoms of dry eye syndrome. Two hundred participants were recruited 
from the patient base of an optometric practice in North Lincolnshire. An initial health and 
lifestyle questionnaire and food recall diary were completed by all participants. Results from an 
Ocular Surface Disease Index (OSDI) questionnaire and from clinical assessments made by the 
researcher were used as outcome measures. 
The aim of the present study was to investigate the relationship between diet and the results 
were from clinical assessment of the tear film in routine optometric practice. Data was collected 
and statistical analysis was carried out on the results obtained. The findings were:
 ♦ There was a significant difference in OSDI score between males and females, showing that 
females had significantly higher OSDI scores than males.
 ♦ Those participants who consumed nuts had a significantly lower OSDI score, a significantly 
higher tear meniscus height (TMH), and significantly higher non-invasive tear break-up time 
(NITBUT) and Tear Break-Up Time (TBUT) than those who did not. 
 ♦ Participants who consumed oily fish had a significantly higher TMH than those who did not.
 ♦ High OSDI scores were found to be significantly associated with lower consumption of Poly-
unsaturated Fatty Acids (PUFAs), carbohydrate and calories.
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Chapter 1: Literature Review
1.1 Background
A literature review was carried out to investigate the current knowledge of the relationship 
between diet and clinical tear analysis. The terms and words used for the searches to find articles 
relating to dry eye and diet included ‘dry eye’, ‘essential fatty acids’, ‘omega 3 and 6’, ‘nutrition’, 
‘Sjögren’s syndrome’, ‘diet’ and ‘antioxidants’. 
A review was carried out to find all relevant studies of the highest level of evidence, published, 
unpublished. Studies were assessed to produce an unbiased summary of the findings of articles 
including those published in peer-reviewed journals. Studies were identified and in the first 
stage using a computerised search of various databases including Pub Med, Science Direct and 
Ovid Medline, Web of Knowledge and Google Scholar. The aim was to identify relevant cross-
sectional studies. In the second stage, copies of the articles were requested and where possible 
obtained. Bibliographies of the retrieved articles were manually searched. In the third and final 
stage, articles were reviewed and relevant information incorporated into this manuscript. UK 
based and International studies were included. 
Study designs considered included in the review were:
 ♦ Double-blind studies
 ♦ Randomised controlled studies
 ♦ Observational studies 
 ♦ Reports detailing the combined meta-analysis of various studies
There was no limit for the number of years within in which the studies had to have been 
conducted.
Once identified, duplicate studies and those involving inappropriate topics were removed. 
Animal studies were not considered. There was a language restriction when reading the studies 
as only ones published in English (including those translated) were considered. However, only 
nine relevant papers written in languages other than English were identified and so these were 
taken as unlikely to have significantly affected the outcome of the review
Wherever appropriate, the quality of the studies was assessed to establish a threshold of the 
quality available and gain an understanding of the relative strength and weakness of the body of 
evidence and distinguish among studies in terms of overall satisfaction. To do this, the following 
checklist had to be met:
1. Research question: Did the authors describe their goal in conducting this research and was 
it easy to understand what they were looking to find? 
2. Study population: Did the authors describe the group of people from which the study 
participants were selected or recruited, using demographics, location, and time period? 
3. Groups recruited from the same population and uniform eligibility criteria: Were the 
inclusion and exclusion criteria developed prior to recruitment or selection of the study 
population? Were the same underlying criteria used for all of the subjects involved? 
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4. Sample size justification: Did the authors present their reasons for selecting or recruiting 
the number of people included or analysed? Did they go further to note or discuss the 
statistical power of the study? 
5. Sufficient timeframe to see an effect: Did the study allow enough time for a sufficient 
number of outcomes to occur or be observed. 
6. Outcome measures: Were the outcomes defined in detail? 
7. Statement regarding possible conflicts of interest for the authors: Was this mentioned in the 
study?
1.2 Results of review
Dry eye syndrome (DES) is a common condition, regarded as an abnormality to the tear film 
which frequently increases with age. It is thought to worsen through a sequence of four 
events: 1,2,3
 ♦ Decreased tear production or increased tear film evaporation (increased tear osmolarity); 
 ♦ Decreased conjunctival goblet-cell density; 
 ♦ Increased corneal epithelial desquamation; 
 ♦ Destabilisation of the cornea-tear interface.
DES may also arise from lid closure abnormalities or environmental conditions e.g. air 
conditioning, central heating and during tasks that require visual concentration e.g. interacting 
with a computer display.
The tear film is a transparent film that is known to have the following functions:4,5
 ♦ Mechanical—for the flushing of cellular debris from the cornea and conjunctival sac; 
 ♦ Nutritional—it nourishes the avascular cornea;
 ♦ Bactericidal—its antimicrobial properties reduce the likelihood of corneal infection;
 ♦ Lubrication—ensuring there is smooth movement of the eyelids over the globe during the 
blink mechanism.
Dry eye syndrome has been defined by the National Eye Institute (NEI) as “a disorder of the 
tear film due to tear deficiency or excessive tear evaporation which causes damage to the 
interpalpebral ocular surface and is associated with symptoms of ocular discomfort.”6 The 
National Eye Institutes’ Dry Eye Workshop Subcommittee (DEWS) produced a definition of dry 
eye disease supported within a comprehensive classification framework which reflected the 
current understanding of the disease. The committee reviewed the definition and classiﬁcation 
presented at the 1995 National Eye Institute (NEI)/Industry Dry Eye Workshop 2007, concluding: 
“Dry eye is a disorder of the tear ﬁlm due to tear deﬁciency or excessive evaporation, which 
causes damage to the inter-palpebral ocular surface and is associated with symptoms of ocular 
discomfort.” 7
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Dry eye syndrome can be divided into two types: aqueous deficient and evaporative.5
1. Aqueous deficient DES which can be further broken down to Sjögren’s and non-Sjögren’s 
dry eye. In the non-Sjögren’s version, it can arise from an obstruction in the lacrimal gland 
resulting in increased tear osmolarity.8
2. Evaporative DES may arise due to a meibomian oil deficiency or lid inadequacies such as an 
incomplete blink or a low blink rate (inability to properly distribute tears).9 
Current treatments usually deal with the management of the tear film, and the conventional and 
main approach to treating DES is instillation of lubricating eye drops or tear substitutes, although 
these do not last very long as topical treatments treat the symptoms and are unable to resolve 
the underlying cause.3 
Dry eye syndrome can also be related to systemic health conditions such as diabetes mellitus, 
thyroid disease, rheumatoid arthritis and systemic lupus erythematosus.6 It has also been 
shown to be related to systemic medications, such as diuretics, antihistamines, antidepressants, 
cholesterol lowering agents, beta-blockers and oral contraceptives.7, 8 Patients suffering from 
DES complain of ocular symptoms such as dryness, grittiness, stinging, burning and general 
discomfort. Presenting signs often include bulbar conjunctival redness, corneal staining, reduced 
tear break up time and tear meniscus height.
1.3 Epidemiology
Epidemiological studies on dry eye syndrome suggest vast differences in prevalence. The 
difficulty in determining the prevalence and extent of DES has stemmed in part from limited 
understanding of the pathophysiology of dry eye. The Dry Eye Workshop Subcommittee 
reviewed major epidemiological studies of dry eye and demonstrated that the prevalence of dry 
eye ranged from 5 to 30 % of individuals aged over 50 years.10 Definitions of DES have differed 
from one study to another with no consensus on criteria for diagnosis, making results difficult 
to compare.10 There has also been a lack of standardised clinical testing protocols to diagnose 
DES, and in addition to this clinical signs show poor reliability resulting in under-diagnosis of the 
condition.10 Patients often just live with the symptoms attributing them to getting older, though 
some will self-treat using products obtained over the counter (i.e., without prescription). Results 
from The Gallup Survey of DES Sufferers (2005), suggest that only one in four people with dry eye 
symptoms consult a primary health care professional.11 
Prevalence of DES more than doubles after the age of 80 years compared to under 60 years and 
being female increases the risk of DES by nearly 50% with an estimated 3.23 million women and 
1.68 million men aged over 50 years suffering from moderate-to-severe DES.1 Increased age and 
being female, especially if peri- or post-menopausal, are risk factors for DES. Postmenopausal 
women may be the largest at-risk group: this is due to a decrease in hormonal levels leading 
to loss of anti-inflammatory protection and decreased lacrimal secretion.10 It is therefore 
commonly accepted that the incidence of DES increases with age and is greater in women, 
especially around and after the menopause. A study on 926 subjects aged 40 years and older, 
found a higher prevalence of DES in women.10 According to another study, women experienced 
a sharp increase in the prevalence of DES earlier than men, around the age of 45, roughly at the 
onset of menopause.13,14 The prevalence of dry eye was reported to be 14.4% in 3,722 subjects 
aged 48 to 91 years and it was noted that the prevalence of the condition doubled after the age 
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of 59.15 A review of several large studies, conducted by the Epidemiology Subcommittee of the 
2007 NEI’s Dry Eye Workshop, confirmed that the prevalence of DES can be up to 30% in people 
aged over 50 years.12
Large epidemiological studies conducted in the US to estimate the prevalence of DES in women 
have confirmed that the prevalence of the condition increases from approximately 5.7% in pre-
menopausal women (aged under 50 years) to 9.8% in women aged over 75 years, concluding 
that DES is prevalent, affecting over 3.2 million American women middle-aged and older.16 The 
same researchers estimated the prevalence for DES among US men in 2009: they concluded that 
prevalence of DES increased with age, from 3.9% among men 50–54 years old to 7.7% among 
men 80 years and older. They further estimated that the prevalence of DES was 1.68 million men 
aged 50 years or older with an expectation that DES would affect over 2.79 million US men by 
2030.17Research conducted in a hospital environment revealed that the incidence of DES among 
ophthalmic outpatients was 0.46% with a male: female ratio of 1:1. Fifty seven percent of the 
patients were above 50 years of age.94 
Dry eye syndrome has been known to occur following corneal surgery and is a known common 
complication of LASIK (Laser Assisted in Situ Keratomileusis).18 This procedure is thought to 
disrupt both the dense sub-basal nerve plexus and stromal corneal nerves in the creation 
of the required anterior stromal flap and excimer laser ablation of the cornea.19 There are 
complex interactions between the afferent sensory nerves of the ocular surface and the efferent 
autonomic nerves to the lacrimal gland that modulate both tear composition and secretion. 
Any factor that disrupts this relationship will lead to tear dysfunction and an increase in the 
concentration of the tear film (hyperosmolarity) which then leads to inflammation and apoptosis 
of the epithelium. The main proposed cause is therefore thought to be iatrogenic corneal nerve 
damage.18, 19 
It has been shown that up to 10% of the non-contact lens wearing population who are under 
the age of 60 years have symptoms of dry eye,20 although, paediatric contact lens wearers aged 
between 8 to 14 years have fewer complaints about dry eyes than adult contact lens wearers. 
This may be due to improved tear film, differences in reporting of symptoms, or modality of 
contact lens wear. For young females wearing contact lenses, researchers concluded that the 
osmolarity of their tears was not affected by contact lens use.21 However, a survey conducted by 
US practitioners showed that up to 50% of the 35 million male and female contact lens wearers 
present to an eye care professional with dry eye symptoms, with 12-21% of soft contact lens 
patients having reduced their wearing time because of these symptoms, and that 6-9 % were so 
symptomatic that they were unable to wear lenses at all.20 
The ocular surface and pre-corneal tear film have been investigated to see if they were 
influenced by the environment. The pre-corneal tear film was shown to be more influenced by 
climatic conditions than by atmospheric pollution.96 
A study in India has revealed that overall the incidence of DES was higher amongst outdoor 
workers and people from rural areas, which may be due to the heat, low humidity, high 
temperature, direct hot air currents and dust, all of which are encountered in tropical climatic 
conditions and could have a drying effect on the pre-ocular tear film and the ocular surface. 
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These conditions, alone or in combination, may initiate or aggravate a dry eye. This study also 
revealed an association between DES and poor socioeconomic status, most probably due to a 
diet lacking green leafy vegetables and/or fruits and also vitamin A.94 
Other researchers similarly concluded that exposure to wind, sunlight, high temperature, and air 
pollution was significantly related to dry eyes. Rural people and those with outdoor occupations 
in tropical climates are more exposed to environmental factors which can affect the tear film and 
ocular surface thus causing dry eye syndrome. 95
1.4 Aetiology
Dry eye syndrome has a multifactorial and elusive aetiology and a wide variety of clinical signs 
and symptoms. There are two main aetiological hypotheses for categorising DES: aqueous-
deficient or evaporative. 5, 6, 7, 9,100,101,102 In 2007, as recommended by DEWS, the scheme 
retained the two major classes of dry eye, as previously determined in the 1995 NEI/Industry Dry 
Eye Workshop classification.103
1.4.1 Aqueous-deficient DES
This is caused by a lack of aqueous tear secretion by the lacrimal glands. It results in 
hyperosmolarity of the tear film and an unstable tear film with desiccation of the ocular surface. 
It is often called aqueous deficient dry eye, or lacrimal insufficiency dry eye. Aqueous deficiency 
is a common accompaniment to auto-immune disorders such as rheumatoid arthritis, lupus and 
Sjogren syndrome which can be further classified as primary or secondary Sjögren  
syndrome. 5,6,7,9
1. Primary Sjorgen is an auto-immune disorder in which the lacrimal and salivary glands are 
infiltrated by T-cells which are activated. The resulting symptoms include dry eye and dry 
mouth.104
2. Secondary Sjögren syndrome is associated with other autoimmune diseases such as 
rheumatoid arthritis.23
Non-Sjögren aqueous-deficient dry eye can result from lacrimal gland insufficiency and lacrimal 
duct obstruction.
1.4.2 Evaporative DES
This is known to have various causes: including meibomian gland disease, eyelid aperture 
disorders or lid/globe incongruity, blink disorders, and ocular surface disorders.23 The most 
common cause is meibomian gland dysfunction (MGD); it is also often referred to a posterior 
blepharitis—which is a common condition of MGD.24 
Meibomian gland dysfunction occurs when the lipid secretion required to control evaporation 
and maintain a normal tear film is abnormal, i.e. lipid layer deficiency. As MGD progresses, 
symptoms develop and lid margin signs, such as changes in meibum expressibility and quality. 
Lid margin redness may also become more visible.25 
The International Workshop on Meibomian Gland Dysfunction proposed the classification of 
MGD into two major categories based on meibomian gland secretion: low-delivery states and 
high-delivery states. Low-delivery states are further classified as hyposecretory or obstructive, 
with cicatricial and non-cicatricial subcategories.105 Hyposecretory MGD describes the condition 
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of decreased meibum delivery due to abnormalities in meibomian glands without remarkable 
obstruction. Obstructive MGD is due to terminal duct obstruction. In the cicatricial form, the 
duct orifices are dragged posteriorly into the mucosa, whereas, in non-cicatricial MGD, these 
orifices remain in their normal positions. High-delivery, hypersecretory MGD is characterised 
by the release of a large volume of lipid at the lid margin that becomes visible on application 
of pressure on to the tarsus during examination.26 Deficiency of vitamin A, which is needed for 
maintaining the health of epithelial tissues, also appears to result in evaporative DES.16
Both aqueous-deficient and evaporative DES give rise to similar signs and symptoms and both 
types lead to increased evaporation and reduced tear film stability. Evaporative DES is generally 
regarded as the most common type although both forms can occur simultaneously in the most 
severe of cases.
1.5 Current treatment methods
1.5.1 Artificial tears
Current treatments usually deal with the management of the tear film, and remain the 
conventional and main approach to treating dry eye.3 The exact mechanism of the treatment 
is difficult to identify as these artificial tear preparations do not recreate the function of the 
tear film, but do seem to have a lubrication effect.27 The instillation of eye drops, sprays or tear 
substitutes reduces the tear osmolarity, improving the electrolyte balance and protecting the 
ocular surface. Lubricants are available without prescription, as general sale list (GSL) or over 
the counter (OTC) products, or pharmacy only (P) medicines requiring a prescription. This form 
of therapy gives only short term relief as topical treatments treat the immediate symptoms by 
lubrication but are unable to resolve the underlying cause.3
Although most tear supplements act solely as lubricants, other actions might include 
replacement of deficient tear constituents, dilution of pro-inflammatory substances, reduction of 
tear osmolarity,27, 28 and protection against osmotic stress.29 
The use of drops with high lubricity index has now become more common. For example, Systane 
drops by Alcon Laboratories have the lowest coefficient of friction and therefore the highest 
lubricity index value compared with other readily available preparations such as GenTeal by 
Novartis Ophthalmics, Refresh Tears and Refresh Endura by Allergan.25
A recent study was carried out to investigate the effect of a single-drop instillation of different 
lacrimal substitutes on tear film thickness assessed with optical coherence tomography in 
patients with mild to moderate dry eye disease.97 The findings indicate that a single instillation 
of eye drops increases tear film thickness in patients with dry eye disease. However, the effect of 
multiple instillation and long-term use of artificial tears on tear film thickness warrants further 
investigation.
1.5.2 Nutrition and dietary intake
The various topical treatment modalities for DES only give only temporary relief from the 
symptoms, and this has prompted research into the development of prevention strategies. 
Nutrients are thought to be important in the maintenance of a physiologically normal tear 
film. Much of the research thus far has focused on polyunsaturated fatty acids (PUFAs) such as 
omega-3 essential fatty acids (EFAs) and omega-6 EFAs and how they are linked to the incidence 
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of dry eye. Generally, omega-3 EFAs can be found in walnuts and oily, cold-water dark fish such 
as tuna and salmon. Omega-6 EFAs are found in meat, corn oil and margarine.22
1.5.2.1 Essential fatty acids
Essential fatty acids (EFAs) are fatty acids that humans and other animals must ingest because 
the body requires them for good health but cannot synthesize them. Essential fatty acids contain 
the carboxyl group (COOH) at one end and so are known as carboxylic acids. 
The EFAs of particular relevance to ocular disease are:
1. omega-3 EFAs 
2. omega-6 EFAs 
The term omega, as it relates to fatty acids, refers to the terminal carbon atom farthest from 
the functional carboxylic acid group (–COOH). The designation of polyunsaturated fatty acids 
(PUFAs) as omega-3 EFAs, for example, defines the position of the first site of unsaturation 
relative to the omega end of that fatty acid. Thus, an omega-3 EFA such as α-linolenic acid 
(ALA), which contains three carbon-carbon double bonds (i.e. sites of unsaturation), has a site of 
unsaturation between the third and fourth carbons from the omega end, see Figure 1.1). 
There are three major types of omega-3 EFA that are ingested in foods and used by the body: 
these are α-linolenic acid (ALA), see Figure 1.1, eicosapentaenoic acid (EPA), see Figure 1.2, and 
docosahexaenoic acid (DHA), see Figure 1.3. Once eaten, the body converts ALA to EPA and then 
to DHA. Generally, omega-3 EFAs are found in fish and fish oils, as well as seeds, oils, green leafy 
vegetables such as broccoli and spinach, nuts and beans.25
Omega-3 EFAs, such as ALA, EPA, and DHA. can be found in nature. Most of the ALA consumed in 
the diet comes from plant sources such as flaxseed, walnuts, pecans, hazelnuts, and kiwifruit.34 
The highest concentrations of EPA and DHA are found in cold water dark fishes such as salmon, 
tuna, and herring.25
Figure 1.1—Chemical structure of alpha-linolenic acid (ALA)30
Figure 1.2—Chemical structure of eicosapentaenoic acid (EPA)30
Figure 1.3—Chemical structure of docosahexaenoic acid (DHA)30
Most of the omega-6 EFAs consumed in the diet are from sources such as poultry, eggs, cereals 
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and whole-grain breads.46 They are also found very commonly in oils such as: corn, peanut, 
safflower, rapeseed, sunflower, soybean, borage, and acai berry.31 (see Figure 1.4).
Figure 1.4—Chemical structure of linoleic acid, a common omega-6 fatty acid.30
Essential fatty acids cannot be produced within the body, but omega-3 EFAs and omega-6 EFAs 
are needed for bodily functioning. Essential fatty acids include linoleic acid (in the omega-6 EFA 
group) and alpha-linoleic acid (in the omega-3 EFA group). Both have a role in the maintenance 
of fluidity, flexibility, and permeability in the body.24
Current estimates of the dietary ratio between omega-3 EFAs and omega-6 EFAs in the western 
world are as low as 1:25. It has been recommended to the public that the ratio should be greater 
than this, ideally1: 4.39 However, the ratio is typically much lower (1:10-30) in a western diet due 
to greater consumption of meat and processed food.35 If too much omega-6 EFA is ingested 
due to a diet high in processed meats and low in unprocessed oils and fish containing omega-3 
EFA, the by-product of excess pro-inflammatory prostaglandins and too little anti-inflammatory 
prostaglandins may lead to dry eye. Over-consumption of omega-6 EFA can lead to heart 
disease, stroke and other degenerative diseases.32 Hence, EFAs have been primarily studied with 
regard to cardiovascular disease and conditions such as rheumatoid arthritis, where omega-3 
EFAs have been found to have anti-inflammatory properties.25,26
Omega-3 EFAs may alleviate dry eye symptoms by reducing inflammatory activity in the body 
possibly by altering the lipid profiles of the meibomian glands, while some components of 
the omega-3 EFAs are thought to stimulate aqueous tear secretion.25 A large prospective, 
randomised, double-masked, placebo-controlled clinical trial of an omega-3 supplement for dry 
eye concluded there is evidence to suggest that certain dietary constituents, such as PUFAs, and 
particularly omega-3 EFAs, may be effective in dealing with the underlying causes of dry eye and 
reduce the risk.27 Omega-6 EFAs may be useful in other ocular disease. A prospective study of 
dietary fat consumption found that diets high in omega-6 EFAs and low in omega-3 EFAs were 
associated with reduced chances of developing primary open angle glaucoma, in particular the 
normal-tension type, by making available omega-6 EFAs prostaglandins and therefore helping 
maintain intra-ocular pressure which does not harm the optic nerve.25
The relevance of unsaturated fatty acids in DES has been investigated. For example, sixteen 
patients suffering from dry eyes had a diet supplemented with unsaturated fatty acids during 
a period of one to four months, in addition to their existing dry eye therapy. The dietary 
supplement of omega-3 EFAs led to an improvement of symptoms and reduction of ocular 
surface staining.25 It is understood that essential fatty acids are important for the production of 
the oily part of the tear film.32 EFAs may enhance the lipid layer of the tear film, thus retarding 
evaporation,33 although the use of essential fatty acids as a nutritional supplement is still 
regarded as a novel treatment for patients with DES.34 There has been interest in the use of 
nutritional supplementation or dietary modification for the prevention and treatment of DES.35
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A short study assessing the effect of oral omega-3 fatty acids on tear break-up time (TBUT), 
Schirmer’s score and Ocular Surface Disease Index (OSDI) demonstrated that oral consumption 
of omega-3 EFA,180 mg EPA and 120 mg DHA twice daily for 30 days, is associated with a 
decrease in the rate of tear evaporation, an improvement in dry eye symptoms, and an increase 
in tear secretion, thus demonstrating that oral consumption of omega-3 EFAs has a definite role 
for DES as it is associated with a decrease in the rate of tear evaporation, an improvement in dry 
eye symptoms, and an increase in tear secretion.42 This study was limited to 30 days. The results 
and conclusions seen here should be confirmed with a study over a longer duration.
Research in Singapore to evaluate the role of dietary supplementation of omega-3 EFA in 
DES was conducted and its response to intervention was monitored by routine tear function 
tests like Schirmer test, TBUT and Rose Bengal staining. Omega-3 EFAs were shown to have 
a definite role for DES.41 A pilot, prospective, randomised, double-masked study over ninety 
days was conducted where patients with dry eye received a daily dose of fish oil.28 This 
involved two patient visits: baseline and final. At these visits, patients completed the ocular 
surface disease index to score subjective symptoms, and had slit-lamp examinations—TBUT, 
corneal staining, Schirmer type I and fluorophotometry. The average tear production and tear 
volume, as indicated by Schirmer testing, was increased in the omega-3 group.28 The observed 
improvement of dry eye relative to symptoms in this placebo-controlled randomised trial is an 
example of a very small sample size of subjects. 
In a much larger sample size of subjects, Miljanović et al39 assessed the diets of 32,470 women 
and also found that those with higher omega-3 fatty acids consumption had decreased risk for 
dry eye. 
In a 90-day, placebo-controlled, double-masked study, patients were randomly assigned to 
receive a daily placebo or a daily capsule containing either 1000 milligrams (mg) of omega-3 
EFAs in the form of flaxseed oil (TheraTears Nutrition) or 450 mg of omega-3 EFAs in the form 
of fish oil containing 450 mg of EPA. Results showed that 7% of symptomatic patients in the 
placebo group became asymptomatic while 70% on the omega-3 EFAs fish oil supplement 
became asymptomatic.32 No trends were seen with the flaxseed oil. Although the results of this 
pilot study could not achieve statistical significance, with only 36 patients, 21 in the active group 
and 15 in the placebo group. The study suggests that the most promising end points for a larger 
clinical trial would include dry eye symptoms, Schirmer test results, and fluorophotometry.
Research has been carried to investigate the importance of nutrition and nutritional 
supplements in eye health and how oral nutritional supplementation alleviates the symptoms 
of DES. One study used 43 subjects randomised and subsequently followed for six months. 
There were two groups in the study. Group 1 (n = 23) was assigned to take two soft geltabs of a 
medical food supplement by mouth twice daily for six months. The four daily geltabs contained a 
total of 1 g of omega-3 EFAs derived from flaxseed oil and 500 mg of omega-6 EFAs derived from 
evening primrose oil. Group 2 (n = 20) was directed to take the medical food supplement in the 
same manner, along with topical cyclosporine, instilled twice daily during the last three months 
of the study. Subjects were evaluated at baseline, month 1, month 3, and month 6. Primary 
outcome measures included tear breakup time (TBUT), conjunctival staining, corneal staining, 
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and change in subjective symptoms. This study concluded that practitioners should at the very 
least consider omega-3 EFA supplementation.36
A study was carried out on 181 patients diagnosed with bilateral moderate dry eye who were 
already being treated with lacrimal substitutes. The patients were randomised in a double-blind 
international study to receive placebo or Nutrilarm (R) capsules (a combination of omega-3 
EFA and omega-6 EFA), twice a day for 6 months. The study confirmed that oral administration 
of double supplementation dietary fatty acids present an additional therapeutic advantage 
in patients suffering from ocular dryness who were already being treated with lacrimal 
substitutes.40 This study indicates that omega-3 supplementation induces improvement to the 
ocular surface with statistical significance (P < 0.001) in contrast to the placebo group (P=0.250). 
Of note, there was a lack in correlation between symptomatic improvement and the Schirmer 
score. This result was in contrast to the pilot study by Wojtowicz et al 39 in which there was 
increase in tear production and volume. The difference in findings between studies could be due 
to the small sample size in their study (n=36). The significant drift in the symptoms and TBUT 
scores in the omega-3 group suggest that dietary supplementation with omega-3 fatty acids 
improves the inherent stability of tear film as compared to tear production.40
Research confirmed that additional intake of nutritional supplementation with omega-3 fatty 
acids at an appropriate consumption ratio with omega-6 fatty acids was found to have a reduced 
incidence of dry eye due to its anti-inflammatory effects. Omega-3 fatty acids may be considered 
as an adjunct therapy to conventional tear substitutes.43 Further research and clinical studies are 
necessary to validate the efficacy and safety of any nutritional supplements. There is currently no 
recommended daily allowance of any EFA, but companies producing such supplements suggest 
between one to three grams per day.
A study entitled The Women’s Health Study investigated the relationship between diet and DES. 
It revealed that dry eye sufferers were more likely to have low levels of omega-3 EFAs in their 
diet, although concluding that further work is required to confirm the potential positive role of 
omega-3 EFAs in the prevention of DES.47 A large epidemiological study conducted on 32,470 
women aged 45 to 84 years, reported that those who consumed more omega-3 EFAs were less 
likely to report DES. Omega-3 EFA is thought to prevent DES by controlling inflammation in the 
tear gland and eye surface.28 Results showed that women with the highest levels of omega-3 
EFAs in their diets had a 20% reduced risk of dry eye compared with women with their lowest 
levels of omega-3 EFAs in their diet. Women who ate at least five servings of tuna per week had 
68% reduced risk of dry eye compared with women who ate one serving per week. The research 
concluded that higher dietary intake of omega-3 EFA is associated with a decreased presence of 
DES in women.28, 35
It is reported that up to 25% of patients consulting eye care practitioners present with dry 
eye symptoms as well as up to 50% of the 35 million contact lens wearers in the USA.44, 45, 46 
Studies focusing on contact lens wearers and the importance of proper nutrition to optimise the 
ocular surface also concluded that essential omega-3 EFAs and omega-6 EFAs in diet showed 
improvement in contact lens patients with DES.46
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In summary, the role of omega fatty acids has shown a reduced incidence of dry eye in tear 
production and secretion. 28, 39, 40, 41 Further evaluation with regards to the role of essential 
fatty acids is an important topic that would benefit from large, multicentre, randomised clinical 
trials to reach a conclusion about the positive effect of certain food types in the prevention and 
treatment of DES.
1.5.2.2 Antioxidants
Antioxidants are man-made or natural substances that may prevent or delay some types of cell 
damage. Antioxidants are found in many foods, including fruits and vegetables. They are also 
available as dietary supplements. Some antioxidants are essential for the functioning of the 
human body: for example, vitamin A is an antioxidant and is an essential nutrient for humans 
because it cannot be synthesised within the body. Certain other antioxidants are not essential: 
for example, lutein which may be obtained from dietary sources.
Vitamin A is obtained from two sources: 
 ♦ Preformed vitamin A from animal products such as milk, fish and liver.
 ♦ Provitamin A (carotene), from plant products such as green leafy vegetables, yellow fruit or 
red palm oil.48
Vitamin A is essential for the normal growth of and maintenance of the integrity of epithelial 
cells and tissues. In the absence of vitamin A, keratinisation of epithelial tissue occurs which 
could result in possible death of the tissue.49
Patel et al 49 assessed the tear stability of 60 healthy subjects and repeated the measurement 10 
days later. Using a double-masked protocol, during the interim period, 66% of the subjects (the 
treatment group) took a commercially available daily dietary supplement and the remaining 
33% acted as controls. Twenty of the treatment group took a daily dietary supplement consisting 
of vitamins (e.g. A, B1, B2, B6, E) and trace elements (e.g. calcium iron, manganese) (VisionACE®, 
Vitabiotics, London, UK), the other 20 subjects took vitamin C tablets. The tear stability of both 
treated groups increased. However, the multi-vitamin and trace element group demonstrated 
more consistent and individually predictable improvement. The tear stability of the control 
group individuals did not significantly change. Further study with a larger number of subjects 
over a longer period would be beneficial.
More recently, the same group investigated the effect of supplementation with vitamins C 
and E on ocular surface cytology specimens and clinical tear film parameters in 60 subjects 
with diabetes, again using vitamin C (1000 mg/day) and vitamin E (400 IU/day) for 10 days.49 
There was a statistically significant increase in goblet cell densities (50 to 59 cells/per field) after 
supplementation along with increased values for the Schirmer test, tear break up time and 
ocular ferning all reflecting an improved tear film quality. The researchers concluded that the 
tear stability of both treated groups increased and therefore supplementation with antioxidant 
vitamins C and E could play an important role in improving the ocular surface milieu.51
A cross-sectional study was carried out involving male patients seen in the Miami veterans 
affairs eye clinic. The patients completed a food frequency questionnaire and a dry eye 
questionnaire. They then underwent measurement of tear film parameters. The main outcome 
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measures included the association of vitamin D levels and DES. Higher vitamin D levels had a 
small but favourable effect on the symptoms of dry eye.48 Research in Australia by Jalbert and 
colleagues suggested potential associations between diet and the health of the tear film. It 
is understood that malnutrition, protein deficiency and in particular vitamin A deficiency are 
extremely deleterious to the health of the eye. Vitamin A deficiency can cause xerophthalmia 
and keratomalacia so supplementation with oral vitamin A would be of clear benefit.49 
Overall, the effectiveness and tolerability of dietary supplementation with a combination 
of omega-3 EFA and antioxidants in the treatment of DES have confirmed that dietary 
supplementation with a combination of omega-3 EFA and antioxidants is an effective treatment 
for DES.52 More cross-sectional studies are needed to determine the indications for the use of 
these nutraceuticals, their required composition and dosage and to fully characterise how they 
modulate the tear film. 50
1.5.2.3 Cholesterol
The leading study available at the time the present study was being carried out was produced 
in South Korea where elevated serum cholesterol was found to be associated with an increased 
risk of dry eye disease in women recruited to the fifth annual Korea National Health and Nutrition 
Examination Survey. Around 15% of the 3219 women in the study were clinically diagnosed 
with dry eye disease.52 Results of this study highlight the significance of eye examinations 
and independent lipid profile monitoring in patients with dyslipidemia because of its possible 
correlation with DES progression.53 Studies investigating the relationship between dry eye 
symptoms and daily intake of a range of dietary components measured using a three-day 
food diary showed that daily intake of cholesterol was significantly related to higher reported 
incidence of scratchiness symptoms in the cohort.54
To summarise, very few studies exist relating cholesterol and DES. The main study carried out in 
Singapore54 shows results specific to the dietary habits of that population: therefore results and 
conclusions of this study needs to be backed up by studies from other parts of the world.
1.5.2.4 Hydration
Adequate daily water intake is recognised to be important for general health. Many would be 
aware of the recommendation to “drink six to eight glasses of water each day”. 108 However, 
interestingly, there is a lack of rigorous scientific evidence to support this advice. The first 
published research carried out to identify if whole-body hydration plays an important role in 
DES hypothesised and confirmed that individuals classified as DES have higher tear osmolarity, 
indicating sub-optimal hydration, compared with those classified as not having DES.55
A small pilot study involving 29 participants with symptoms of dry eye, about three-quarters of 
participants reported a decrease in symptomatology after being advised to increase their daily 
water intake for two-weeks.106 Research subsequently has compared changes in tear osmolarity 
using TearLab®. Results revealed tear osmolarity increased with dehydration.56 These results 
were confirmed by other researchers looking to determine if tear fluid osmolarity changes 
due to hydration status during exercise and post exercise rehydration.107 Tear osmolarity 
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decreased or remained approximately the same after rehydration for most subjects.57 Sherwin 
et al hypothesised that hydration status may affect the eye in both healthy and disease states. 
The researchers performed a systematic review of the current evidence implicating clinical 
correlations of changes in hydration in major common eye diseases. Their findings suggested 
that systemic hydration status broadly affects a variety of ocular processes and disease states 
and therefore dehydration may be associated with development of DES.58
On the whole, later research confirms what was found in the first published research carried 
out to investigate if whole-body hydration plays an important role in DES.55 Further research 
is needed to rigorously evaluate the value of altering hydration status to treat the signs and 
symptoms of DES.
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1.6 Rationale and aim for this research study
Although not sight-threatening, DES is an ocular disorder that can severely reduce quality of 
life: ageing of the population means that DES is likely to become more common. Studies have 
shown that the degradation of ocular optical qualities related to DES is associated with visual 
impairments noticed during critical tasks such as driving. These impairments result from changes 
in aberration caused by changes in tear film.72 It is important to investigate the development of 
prevention or reduction strategies. Large prevalence studies and studies relating dietary intake 
with dry eye have been conducted in other parts of the world but few studies and data are 
available for the U.K. 
Differences will exist between countries with regard to dietary habits and preferences as well as 
socioeconomic, religious and environmental factors contributing to the different foods which are 
consumed by populations based in different parts of the world. 
The subjects of the present study were based in a North Lincolnshire town in the U.K. and their 
dietary habits are likely to vary slightly from those of people in other areas of the U.K.
The aim of the present study was to investigate the relationship between diet and clinical 
assessment of the tear film in routine optometric practice. In the next chapter, the methods for 
the study will be presented.
24
Chapter 2: Methods
2.1 Aim
In Chapter 1, the literature pertaining to the aetiology and epidemiology of DES, and to the 
relationship between nutrition and DES, was presented. The present chapter describes the 
methods used in this study to assess a group of patients in a routine optometric practice in order 
to investigate the relationship between dietary intake and clinical assessment of DES.
2.2 Ethical approval
This study was approved by the Aston University Ethics Committee (ethics application number 
367) and the work conforms to the tenets of the Declaration of Helsinki. A copy of the ethics form 
and letter from the University Ethics Committee can be found in Appendix 1.
This study involved recruitment of participants with and without the signs and symptoms of 
DES from the patient base of a clinical practice located in the United Kingdom. The nature of the 
study was explained to each participant in person by the researcher and an information sheet 
handed to each participant. Informed consent was obtained by explanation of the study and 
possible consequences of taking part. A copy of the subject information sheet and consent form 
was retained by the subject, this can be found in Appendix 2. All participants were informed that 
they were under no obligation to participate, and that they could withdraw at any time. 
2.3 Subjects and recruitment
2.3.1 Inclusion and exclusion criteria 
The aim was to explore relationships between DES symptoms and nutrition in a general sample 
of the population as found in an optometric practice. Participants were not selected on the basis 
of having, or not having, DES.
For inclusion participants had to:
1. Be over the age of 18
2. Agree to provide written informed consent.
3. Be available for one visit to the research centre. 
Participants were excluded from the study if:
1. They had a history of any other anterior ocular pathology other than dry eye
2. They were taking medication affecting the ocular surface
3. They had undergone refractive surgery in the past
4. They had used eye drops within the 24 hours prior to data collection.
The analysis was controlled for smoking and contact lens wear. 
In all, two hundred participants were recruited, all of whom were Caucasian. Participants were 
recruited from the staff and patients of a community optometric practice in a town in North 
East Lincolnshire, England over a period of 18 months. Advertisements requesting participants 
were placed in the waiting room of the practice. A copy of the advertisement can be found in 
Appendix 3.
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2.4 Baseline data collection
2.4.1 Health and lifestyle questionnaire
An initial health and lifestyle questionnaire was completed by each participant. This 
provided information about general health, medication, Body Mass Index (BMI), nutritional 
supplementation, smoking history, ocular health and contact lens wear. A copy of the 
questionnaire can be found in Appendix 4.
2.4.2 Dietary Intake and nutritional software
There are several methods available to help assess the dietary intake of an individual. 
Food diaries can be used to assess current intake, as can 24-hour recalls, food frequency 
questionnaires (FFQ) or taking detailed dietary history. There is no gold standard in dietary 
assessment methods. All methods have their own strengths and weaknesses. The most common 
problem is unreliability because of misreporting.59, 60 Food diaries and 24-hour dietary recall 
diaries are the most accurate methods when estimating mean intakes as they are the only 
methods that provide data on foods actually eaten. Both the food frequency questionnaire and 
the diet history are based on the long-term eating habits of the subject.
For this study, a 24-hour food recall diary was chosen, in preference to an FFQ, as FFQs have been 
found to result in an over-estimation of foods eaten less often, or a bias towards foods perceived 
as ‘healthy’ such as fruit and vegetables. There is some evidence that over-estimation increases 
with the length of the food list and therefore measurement error with FFQs is likely to be greater 
than that with other methods such as food diaries.61 
A single 24-hour recall is also thought to be more useful to obtain a snap shot of dietary intake in 
a large group.62, 63 National surveys have been known to use the 24-hour recall methods, mainly 
due to their high response rate and ability to obtain detailed information in a short time frame.59 
However, a single 24-hour recall may not be considered to be representative of habitual diet 
at an individual level: therefore repeated 24-hour recalls are becoming more popular to assess 
typical dietary habits.62 A repeated 24-hour recall was performed over two non-consecutive 
days including one weekend day. This method increases the likelihood of capturing accurate 
habitual dietary habits and to permit estimation of within-person day-to-day variability. 59 62 63 
A high degree of cooperation and motivation from subjects, in particular from the elderly, is 
required as people can become easily fatigued and frustrated with long dietary history records 
which may be more problematic due to the limitations of memory.64, 65 During the present 
study, this possibility was minimised by encouraging immediate input into a diary with exact 
detail such as ‘two slices of thin sliced brown toast, thinly spread with butter’.
A copy of the food recall diary can be found in Appendix 5. 
As mentioned earlier, the recall diary was completed over a 24-hours weekday and a 24-hours 
weekend day and, for the sake of consistency, the researcher interviewed all the participants in 
order to retrieve the information.
Nutritional software a la calc was chosen to extract the nutritional information gathered from the 
food diary. A la calc was easy to use and allowed the input of the information from the food diary 
in a simple but detailed manner. It produced nutritional results which were concise and easy 
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to extract. Each participant’s food was entered into the software as a ‘recipe’, which allowed the 
software to extract forty nutritional characteristics and most essential nutrients. 
A la calc was founded in 2011 in the UK by Richard Fong, Simon Funke and Kin Fong as a way 
to find the total nutrient content of a recipe by summing up the included ingredient nutrition 
content and accounting for weight lost in the cooking process of the food. The key target 
customers for a la calc are manufacturers, caterers, restaurants, cafés, sandwich makers and other 
food outlets. A la calc was chosen over other dietary analysis programmes because of the range 
of nutrients analysed, ease of use and compatibility with statistical analysis software, accessibility 
and cost. 
The team behind the a la calc software confirmed that for accuracy and validity a la calc relies 
on three recognised nutritional databases for its calculations. These three databases contain 
thousands of ingredients in various states e.g. raw/cooked/frozen.and all use data that is 
updated regularly thus ensuring that calculated data from a la calc is always reliable and correct.
The three databases used within a la calc are: 
1. A UK ingredient database maintained by McCance and Widdowson and officially approved 
by the relevant UK government organisations as the UK nutrient databank. 
2. A US database data provided by the US Department of Agriculture (USDA): this is the official 
database for use in the US.
3. The third database is maintained by a la calc and is used for specific ingredients, including 
stabilisers, preservatives and flavour enhancers: this data is sourced from UK manufacturers 
of those products.
All a la calc calculations conform to the EC Directive 90/496/EEC which is used for professional 
nutritional labelling. The nutritional content is determined from the diet diary completely. The 
a la calc software uses a ‘calculation’ method to obtain nutrient value. For each ingredient in the 
recipe:
Ingredient nutrient value = nutrient content of the ingredient  × weight of the ingredient
Recipe nutrient value = sum of all individual ingredient nutrient values 
Unless, the nutrient is water, in which case:
Recipe nutrient value = sum of all individual ingredient nutrient values −
total weight of all input ingredients 
× weight lost in the cooking process
This total nutrient value is then scaled to a value per 100 grams.
The calculation assumes that all the weight lost in cooking is due to moisture which has 
evaporated.
The results obtained from the software were divided in two to average for one day as the data 
related to a two-day diary (one weekday and one weekend day). Brunner et al. confirmed that 
dietary analysis using the use of food diaries is reported to be well correlated with nutrient 
biomarker levels.66
{ {} }
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An alternative to the ‘calculated’ method as used by a la calc would have been a ‘lab analysis’ 
method. However, the calculated method was preferred for the following reasons:
 ♦ Lab results are accurate to the portion of food sent in the sample. Calculated results are 
based upon average ingredient nutrient content.109
 ♦ Nutrient content for an ingredient can vary season to season or specimen to specimen. For 
example, a summer carrot may have higher nutritional content than a winter carrot due to 
temperature, heat and light changes.110
 ♦ Calculated methods cannot take into account physical deforming of nutrient molecules 
caused by extreme cooking methods.111
 ♦ Both calculated and lab results are accepted by the UK Food Standards Agency for showing 
on retail packs the nutritional content of food. Benefits of the a la calc software included 
the ability to extract information about the consumption of antioxidants such as vitamins 
A, C, E and zeaxanthin, and of carbohydrates (some of which are sugars), cholesterol and 
calories. The limitations of this software include inability to extract omega-3 or omega-6 
nutrient values from polyunsaturated fatty acids. To allow for this, it was noted whether the 
participant had consumed nuts or oily fish.
2.4.3 Dry eye questionnaire
There are a number of other dry eye questionnaires available, including:
 ♦ Ocular Surface Disease Index (OSDI) 63, 64
 ♦ McMonnies Dry Eye Index 63, 64
 ♦ Ocular Comfort Index (OCI) 64
 ♦ National Eye Institute Visual Functioning Questionnaire 65
For this study, it was determined that the dry eye questionnaire to be employed should meet the 
following criteria: 
1. The questionnaire must have been validated.63,64
2. The questionnaire must be readily available and appropriate for practitioners.65
The OSDI questionnaire was chosen as studies have shown it to be a valid and reliable 
instrument for measuring the severity of dry eye disease.67 This questionnaire uses a 12-item, 
5-category Likert scale that investigates symptoms, triggers and consequences of dry eye.68  
It utilises the twelve questions to assess the level of discomfort and how dry eye syndrome 
interferes with daily living tasks. Five of the twelve questions relate to ocular symptoms, four to 
functional tasks and three to environmental triggers.
It is generally accepted that an OSDI score of around 30 or over is necessary for diagnosis of 
severe DES.70 Studies have shown that the OSDI correlated significantly with the McMonnies 
questionnaire, the National Eye Institute Visual Functioning Questionnaire, the physical 
component summary score of the Short Form-12, patient perception of symptoms, and artificial 
tear usage.69 It is suggested that the OSDI score is proportional to symptom intensity.69 
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For the sake of consistency, the researcher interviewed all the participants for the completion of 
the questionnaire. A copy of the OSDI questionnaire can be found in Appendix 6.
2.5 Clinical data collection
Subjects were assessed by the researcher using clinical techniques found in routine optometric 
practice. The results were recorded and a copy of the data collection form can be found in 
Appendix 7.
A strict protocol was developed for data collection. The assessment was conducted in a stable, 
air-conditioned environment where the temperature in the consulting room was maintained 
at 20 degrees centigrade. Subjects remained in this environment between measurements as 
recommended in the International Dry Eye Workshop report.71 
2.5.1 Non-Invasive tear break-up time (NITBUT)
There is concern that the presence of fluorescein in the tear film will destabilise the  
tears and for this reason the tear film was measured non-invasively without first instilling 
fluorescein.72,73,74 This type of tear film measurement is referred to as non-invasive tear break-
up time (NITBUT). It should however be noted that changes in the tear meniscus curvature has 
been observed even with this minimally invasive technique confirming that it is easy to induce 
minor degrees of reflex tearing, even during delayed blinking.75 A Bausch & Lomb (one-position) 
variable doubling keratometer was used to observe the distortion and/or break up time of the 
keratometer mire (a reflected image of a keratometer grid). The researcher focused and viewed 
the crisp mires and then recorded the time for the mire image to break up. For a reliable clinical 
estimate of the NITBUT, it is recommended taking three measures of NITBUT: this can then be 
confidently used as a representative value of tear stability time.112  Three consecutive readings 
were evaluated and the median noted. This is an established clinical test that is routinely used in 
optometric and ophthalmological practice.
2.5.2 Tear meniscus height (TMH)
A normal pre-ocular tear film should be continuous over the cornea, conjunctiva and lid margin. 
The height of the tear meniscus can give an indication of tear volume. This was measured by a 
slit-lamp biomicroscope with a graticule in 0.05 mm units at the centre of the lower lid margin. 
This measurement is normally a one-time snapshot during the inter-blink period. Although the 
tear system is dynamic and obviously, the tear meniscus can keep changing from time to time 
and is affected by many factors, like glare and heating.113 The slit was positioned horizontal to 
the lower lid with indirect illumination, to exclude these invasive factors. The TMH was measured 
directly below the pupil centre.
Tear meniscus height is classified: 
 good: greater than 0.2 mm;  
normal: 0.2 mm;  
poor: less than 0.2 mm.76 
Many studies have demonstrated that there is good correlation between TMH and symptoms of 
dryness.77,78,79 
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In the present study, three consecutive readings were taken and the median noted. This is an 
established clinical test that is routinely used in optometric and ophthalmological practice. 
A study by Mainstone et al found that TMH has strong correlations with non-invasive breakup 
time and is the most powerful predictor of tear film insufficiency. The conclusion was that 
TMH is a useful alternative to existing tests for dry eye.114 However, the main limitation of tear 
meniscus assessment remains the lack of universally accepted normative data and cut-off values 
for normal eyes. Mean TMH values range from 0.12 ± 0.04 to 0.46 ± 0.17 mm in healthy eyes and 
from 0.13 ± 0.07 to 0.24 ± 0.09 in the case of dry eye.115
2.5.3 Tear break-up time (TBUT)
Tear stability is routinely assessed in clinical practice to aid in the diagnosis of DES. Assessing the 
tear film can be difficult as the tear film is transparent: fluorescein dye can be introduced into the 
tears to make observation of the tear film break up easier. 
In the present study, fluorescein stain was applied into the temporal lower palpebral conjunctiva 
of the eye by a moist Fluoret—a paper strip impregnated with approximately 1mg fluorescein 
sodium Ph.Eur. When wet with a sterile drop the resulting orange dye fluoresces green when 
excited by blue light. Following instillation the patient was asked to blink a few times to spread 
the dye over the surface of the eye. The uniform green film was observed and the time recorded 
for black patches to start to appear, as these are signs of the tear film breaking up. The tear film 
was assessed using a narrow slit, full-beam slit-lamp biomicroscope. The number of seconds 
taken for the tear film to break up was recorded. The break up was seen as diffuse dark patches 
which appeared within the spread of fluorescein over the cornea.
This technique of assessing stability of the tear film is sometimes thought of being controversial, 
even though it is widely used. It can be made more reliably when conducted using a full-
beam observation of the cornea is used to scan the cornea with a narrow slit in making the 
measurements.116 Three consecutive readings were evaluated and the median noted. This is an 
established clinical test that is routinely used in optometric practice: in fact, fluorescein staining 
for assessing tear break-up time is the most frequently used test for DES diagnosis.80 Despite the 
possibility of wide variation in TBUT among individual subjects, there is general agreement that a 
TBUT shorter than 10 seconds reflects tear film instability and a TBUT shorter than 5 seconds is a 
definite marker of dry eye.81 
This technique is the most widely used clinical test for assessing tear instability and therefore 
measurement of TBUT.117,118 One study has concluded the reproducibility of TBUT is high in 
the general population but significantly greater in patients with dry eyes.82 In contrast, another 
study has recognised that TBUT has poor accuracy and so best conducted with other clinical 
measures.119  The main characteristic of the test that may contribute to its poor performance is 
the variability in the volume of fluorescein instilled.120, 121 The original tear volume is a minute 
volume, and addition of even a tiny amount of fluorescein solution significantly disturbs native 
tear dynamics. A study showed that moistened fluorescein strips can deliver an inconsistent 
minute volume of fluorescein to the ocular surface, which, in turn, directly affects the TBUT 
measurement obtained.121 However, Finnemore et al showed that when wet with a sterile drop, 
a fluorescein strip is designed to deliver a relatively accurate but very limited dose of from 0.5 ml 
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to 1.0 ml of liquid to the surface of the cornea, thus minimising variability.122 This may explain 
why, overall, studies that use fluorescein strips, which deliver a minimal volume of fluorescein, 
result in a relatively reliable and repeatable reading.123,124 
Several questions about TBUT are still unanswered and warrant further study: to determine 
which method of fluorescein delivery produces the most reliable results for repeatability and 
sensitivity/specificity in detecting dry eye.123
2.5.4 Corneal and conjunctival staining 
In patients with DES, one or all of the corneal or conjunctival surfaces or the intracellular surfaces 
becomes compromised.83 Staining agents allow these changes to be viewed. Corneal staining is 
believed to occur when fluorescein enters damaged epithelial cells.84 85 Some degree of staining 
is found in up to 79% of corneas in healthy non contact lens wearing patients.85 This form of 
staining is a measure of epithelial integrity and is widely used in clinical and research settings. 
Grading scales are now used extensively in optometric practice for a variety of purposes 
including the anterior eye examination. This tool can now be considered as an expected norm in 
practice. The incorporation of grading scales is advocated for good optometric clinical practice.
Various clinical grading scales were considered including the original CCLRU rebranded IER 
and more recently published under the name of the Brien Holden Vision Institute or BHVI, 
and Efron grading scales. The latter consists of a series of artist-rendered depictions of 16 
different conditions, while the former comprises photographs of six conditions, two of which 
are presented in multiple manifestations. The Efron grading scales were chosen for this study 
and according to Professor Nathan Efron, who developed these scales, the advantage of using 
an artist-rendered (versus photographic) grading scales is that the desired level of change can 
be depicted, with all other factors being kept constant, thus avoiding potentially confounding 
artefacts and allowing artistic licence to add clarity.125  The primary design criteria in developing 
the Efron grading scales were simplicity and ease of use by clinicians. Complications are 
illustrated in five stages in severity (from 0 to 4), with traffic light colour banding from green 
(normal) to red (severe). The artist-rendered systems generally afford lower grading estimates 
and better grading reliability than the photographic systems.86, 87
Efron grading scales are validated for clinical use and show a linear change between grades. 
Practitioners can expect to use them with average 95% confidence limits of ±1.2 grading scale 
units.86
In this study, the cornea and the conjunctiva were assessed using fluorescein stain when 
measuring TBUT: Efron scales were used to record staining by type, depth and extent.
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2.5.5 Protocol for data collection
1. Consent was taken by the researcher and a unique identification code created.
2. All data was collected by the researcher. 
3. A health and lifestyle questionnaire was completed by the subject.
4. The subject was interviewed by the researcher for the food diary recall.
5. The researcher carried out the collection of clinical data a minimum of ten minutes after 
subject arrived to allow for acclimatisation to the indoor environment:
 1.1 Eye chosen for assessment
 1.2 Vision measured in chosen eye
  1.3 Visual acuity measured in chosen eye
 1.4 Non invasive tests carried out: 
  1.4.1 NITBUT measured.
  1.4.2 TMH measured.
 1.5 Invasive Tests carried out:
  1.5.1 TBUT measured.
  1.5.2 Assessment of fluorescein corneal staining.
  1.5.3 Assessment of fluorescein conjunctival staining.
 1.6 The researcher interviewed the subject for the OSDI questionnaire
2.6 Data entry and analysis
Data from the health and lifestyle questionnaire, OSDI, A la calc and the clinical assessment were 
entered into Microsoft Excel v12.0 (Microsoft Office 2007, Microsoft Corporation, Washington, 
USA). The data were then exported for statistical analysis into SPSS v23.0 (IBM SPSS 23 software 
(IBM Corporation, New York, USA). 
Each data set was checked for normality using the Kolmogorov-Smirnov test statistic which 
asseses the normality of distribution of the data. Where found to be normally distributed 
(significance value less than 0.05), the appropriate parametric test was used for statistical 
analysis. Where non-normally distributed, the appropriate non-parametric equivalent tests were 
used.
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2.6.1 Sample size 
Sample size data for comparison between groups has been calculated based on published mean 
and standard deviation tear film data 88 and shown in Table 2.1.
The means and standard deviations are taken from a publication by Lira et al 88. The difference 
to detect values were determined to keep the values as small as possible to reflect realistic 
differences between groups. The difference in values as a percentage of the mean values are all 
between 10 and 20 %. 
TMH (mm) NIBUT (sec) TBUT (sec)
Mean / 
Standard Deviation
0.30 / 0.14 6.58 / 2.62 6.68 / 1.99
Difference to detect 0.06 1.5 1.5
Effect size 
(Difference to detect / SD) 0.35 0.57 0.75
Sample size 
(32 / effect size2) 174 100 57
Table 2.1
Sample size data for comparison between groups
The maximum number of participants calculated was 174 for TMH. The recruitment target was 
set at 200 participants to allow for drop out.
Although considered controversial by some researchers, post-hoc sample sizes were carried out 
using mean and standard deviation data from the data collected in this study, and are included 
here for comparison. These sample sizes are shown in Table 2.2
NITBUT 
(sec) TBUT (sec) TMH (mm)
Total 
corneal 
staining
Total 
conjunctival 
staining
OSDI
Mean / 
Standard Deviation 4.08 / 1.79 3.68 / 1.72 0.38 / 0.13 2.32 / 3.67 10.04 / 4.57 24.01 / 20.01
Difference to detect 1.50 1.50 0.06 2.40 2.40 10.00
Effect size 
(difference to 
detect / SD)
0.84 0.87 0.38 0.65 0.53 0.50
Sample size 
(32 / effect size2) 46 42 179 75 116 128 
Table 2.2
Post-hoc sample size data
2.7 Summary
In this chapter the methods for the cross-sectional study of the relationship between clinical 
evaluation, OSDI and dietary intake have been described. Chapter 3 will report on the baseline 
characteristics of the cohort.
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Chapter 3: Descriptive and subgroup analysis
This chapter will outline the characteristics of the cohort and also examine differences between 
sub-groups and outcome measures.
3.1  Descriptive statistics
Two hundred participants were recruited all of whom were white British. Pre-existing signs and 
symptoms of DES were not a requirement for participation. The mean age of the subjects was 56 
years (mean ± sd 56 ± 19, range 21 to 89 years). The median age was 60 years. One hundred and 
fourteen of the participants were female (57%), 15 were smokers (7.5%), 17 were contact lens 
wearers (8.5%). 
As mentioned in the previous chapter, a TBUT of less than 5 seconds is generally considered 
indicative of DES,81 and the mean TBUT for this cohort was 3.68 seconds (median 3 seconds). It 
was found that 168 subjects (84%) were found to have TBUT of less than 5 seconds. Conversely, 
a TMH greater than 0.2 mm is considered ‘good’, 76 and this cohort had a mean THM of 0.38 mm 
(median 0.3mm). Only two subjects from the 200 (1%) were found to have THM less than 0.2mm.  
An OSDI score of over 30 is generally needed to diagnose DES70 and Table 3.1,below, reveals the 
mean OSDI score of the whole group to be 24.01 (median 16.67). It was found that 85 subjects 
(43%) had an OSDI score over 30.
The mean intake of PUFA for the group was 16.63 g which is comparable to the recommended 
daily intake (RDI) 16 g.126,127 The mean intake of other nutrients such as saturated fat, 
carbohydrates, vitamin C, vitamin E, and cholesterol were all lower than the recommended daily 
intake (RDI). Details of the characteristics of the whole cohort alongside what is regarded as 
normal values and RDI can be found in Table 3.1 (next page), with graphical representation in 
Figure 3.1, page 35.
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Whole group Mean / 
Standard Deviation
Median Normal Values
Recommended
Daily Intake
Age (years) 56.2 / 19.9 60.00
Height (metres) 1.7 / 0.2 1.70
Weight (kg) 70.7 / 14.5 70.9
BMI 25.05 / 7.49 24.10
Vision (logmar) 0.45 / 0.37 0.50
VA (logmar) 0.07 / 0.12 0
NITBUT (seconds) 4.1 / 1.8 4.00 10
TMH (mm) 0.4 / 0.1 0.30 0.2
TBUT(seconds) 3.7 / 1.7 3.00 10
TOTAL 
Corneal staining score 2.32 / 3.67 1.00
TOTAL 
Conjunctival staining score 10.04 / 4.57 10.00
Total OSDI score 24.01 / 20.01 16.67
Polyunsaturated fatty acids (g) 16.63 / 8.80 15.50 16
Energy (kcal) 1251.07 / 470.73 1273.00 2500 †
Saturated Fat (g) 7.74 / 3.90 7.00 20.0
Carbohydrates (g) 59.69 / 40.36 47.00 275
Vitamin C (mg) 48.95 / 54.89 31.70 60
Vitamin E (mg) 5.21 / 3.59 3.80 15
Cholesterol (mg) 161.88 / 99.12 157.80 300
Table 3.1
Mean, standard deviation and median values for anthropometric, dry eye  
and dietary factors for the whole cohort, alongside RDI.126 127
(n=200)
†
Average requirement suggested by  the European 
Food Safety Authority for males and females aged 
between 30 and 79 years.151
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Figure 3.1
Age distribution of participants.
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3.2 Age subgroups
The cohort was divided into subgroups for two age groups: participants aged 50 years and under 
and those over 50 years. Initial results revealed a lower mean NITBUT and TMH in the over 50 years 
subgroup. See Tables 3.2, below, and 3.3, next page.
 50 years and under Mean /  
Standard Deviation
Median Normal Values
Recommended 
Daily Intake
Height (metres) 1.7 / 0.2 1.70
Weight (kg) 71.7 / 15.1 70.00
BMI 25.02 / 7.35 25.00
Vision (logmar) 0.45 / 0.37 0.50
VA (logmar) 0.08 / 0.13 0
NITBUT (seconds) 4.2 / 1.9 4.00
TMH (mm) 0.4 / 0.1 0.40 10
TBUT(seconds) 3.6 / 1.6 3.00 0.2
TOTAL corneal staining score 2.47 / 3.88 2.00
TOTAL conjunctival staining 
score 10.12 / 5.24 10.00 10
Total OSDI score 23.74 / 22.44 23.00
Polyunsaturated fatty acids (g) 18.28 / 9.65 18.00 16
Energy (kcal) 1314.64 / 488.06 1301.00 2500 †
Saturated Fat (g) 7.79 / 3.72 7.00 20.0
Carbohydrates (g) 60.93 / 44.40 58.00 275
Vitamin C (mg) 46.83 / 57.07 46.00 60
Vitamin E (mg) 5.22 / 3.65 5.00 15
Cholesterol (mg) 168.99 / 91.43 160.00 300
Table 3.2
Mean, standard deviation and median values for dry eye and dietary factors for the 
50 years and under sub-group, alongside RDI.
(n = 78)
†
Average requirement suggested by  the European 
Food Safety Authority for males and females aged 
between 30 and 79 years.151
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Over 50 years Mean / 
Standard Deviation
Median Normal Values
Recommended
Daily Intake
Height (metres) 1.7 / 0.2 1.70
Weight (kg) 70.1 / 14.2 70.90
BMI 25.16 / 7.61 24.10
Vision (logmar) 0.46 / 0.37 0.50
VA (logmar) 0.07 / 0.1 0
NITBUT (seconds) 4.0 / 1.8 4.00 10
TMH (mm) 0.4 / 0.1 0.30 0.2
TBUT (seconds) 3.7 / 1.8 3.00
TOTAL corneal staining score 2.22 / 3.54 1.00 10
TOTAL conjunctival staining 
score 9.99 / 4.12 10.00
Total OSDI score 24.18 / 18.33 16.67
Polyunsaturated fatty acids (g) 15.58 / 8/07 15.50 6
Energy (kcal) 1210.42 / 456.7 1273.00 2500 †
Saturated fat (g) 7.71 / 4.03 7.00 20.0
Carbohydrates (g) 58.90 / 37.7 47.00 275
Vitamin C (mg) 50.31 / 53.64 31.70 60
Vitamin E (mg) 5.20 / 3.57 3.80 15
Cholesterol (mg) 157.33 / 103.85 157.80 300
 
Table 3.3
Mean, standard deviation and median values for dry eye and dietary factors for the 
over 50 years sub-group alongside RDI.126,127
(n = 122)
†
Average requirement suggested by  the European 
Food Safety Authority for males and females aged 
between 30 and 79 years.151
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3.2.1 Statistical analysis 
The difference between the independent sub-groups and the outcome measures was 
statistically assessed. According to the Kolmogorov-Smirnov statistic, none of the variables in 
the cohort were found to be normally distributed (significance value less than 0.05). For this 
reason the Mann-Whitney U Test was then used to investigate the difference in dry eye outcomes 
between the two age category subgroups. 
The analysis revealed that there was no statistically significant difference in the dry eye outcome 
measures and between the age in the two sub-groups. This is likely to be due to the mean age of 
the subjects 50 years and under being 48.62 and over 50 being 58.18. These two age categories 
had a difference in means of only 10 years. As a result, there was not a significant difference in 
the dry eye outcome measures between the two age groups as the ages themselves did not 
differ enough from the cohort. Lifestyle factors such as differences in the smoking or contact lens 
wearing habits between the two groups may have had an effect on the results as 90% of 50 years 
and under and 94% of over 50 years did not smoke. Also, 92% of 50 years and under and 91% of 
over 50 years did not wear contact lenses. See Table 3.4, below.
50 years and under Over 50 years
N
Mean / 
Standard 
Deviation
Median N
Mean / 
Standard 
Deviation
Median Z p
Age 48.62 / 17.92 48.00 58.18 / 19.20 59.00  – 0.21 0.83
OSDI score 78 23.74 / 22.44 23.00 122 24.18 / 18.33 16.67  – 0.77 0.44
TMH (mm) 78 0.40 / 0.13 0.40 122 0.38 / 0.13 0.30  – 0.94 0.35
NITBUT 
(seconds) 78 4.22 / 1.85 4.00 122 3.99 / 1.75 4.00  – 0.72 0.47
TBUT (seconds) 78 3.60 / 1.56 3.00 122 3.73 / 1.81 3.00  – 0.03 0.98
Total corneal 
staining 78 2.47 / 3.88 2.00 122 2.22 / 3.54 1.00  – 0.45 0.65
Total 
conjunctival 
staining
78 10.12 / 5.24 10.00 122 9.99 / 4.12 10.00  – 0.54 0.59
 
Table 3.4
Z and p values for relationships between the sub-groups 50 years and under and 
over 50 years and dry eye outcomes.
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3.3 Male and female subgroups
The cohort was divided into male and female subgroups for statistical analysis. When divided 
into the subgroups, the lower mean NITBUT, TMH and TBUT in the female subgroup revealed a 
greater indication of DES than for the male subgroup. This was also evident in the OSDI score, 
which was greater in females than males. See Table 3.5 and Table 3.6, together with Figures 3.2, 
3.3 and 3.4 on page 40.
Males Mean / 
Standard Deviation Median
Age (years) 56.0 / 21.4 60.00
Height (metres) 1.7 / 0.2 1.70
Weight (kg) 70.5 / 14.2 70.90
BMI 24.95 / 7.53 24.10
Vision (logmar) 0.46 / 0.36 0.50
VA (logmar) 0.06 / 0.10 0
NITBUT (seconds) 4.3 / 1.9 4.00
TMH (mm) 0.4 / 0.1 0.30
TBUT(seconds) 3.9 / 1.8 3.00
TOTAL corneal staining score 2.17 / 3.49 2.00
TOTAL conjunctival staining score 9.74 / 4.62 10.00
Total OSDI score 21.65 / 21.22 16.67
Polyunsaturated fatty acids (g) 17.42 / 9.39 18.00
Energy (kcal) 1293.99 / 494.1 1273.00
Saturated Fat (g) 7.92 / 3.78 8.00
Carbohydrates (g) 59.61 / 37.45 60.00
Vitamin C (mg) 45.44 / 45.75 31.70
Vitamin E (mg) 5.22 / 3.47 3.70
Cholesterol (mg) 171.55 / 108.30 157.60
Table 3.5
Mean, standard deviation and median values for dry eye and dietary factors for 
males.
(N=86)
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Females Mean /  
Standard Deviation Median
Age (years) 56.3 / 18.8 60.00
Height (metres) 1.7 / 0.2 1.70
Weight (kg) 69.6 / 14.71 70.90
BMI 25.12 / 7.49 24.10
Vision (logmar) 0.45 / 0.37 0.50
VA (logmar) 0.08 / 0.13 1.00
NITBUT (seconds) 3.9 / 1.7 3.00
TMH (mm) 0.4 / 0.1 0.30
TBUT (seconds) 3.5 / 1.6 3.00
TOTAL corneal staining score 2.43 / 3.82 2.00
TOTAL conjunctival staining score 10.26 / 4.54 10.00
Total OSDI score 25.77 / 18.96 16.67
Polyunsaturated fatty acids (g) 16.04 / 8.32 15.50
Energy (kcal) 1218.68 / 451.8 1273.00
Saturated Fat (g) 7.60 / 4.0 7.00
Carbohydrates (g) 59.76 / 42.59 60.00
Vitamin C (mg) 51.60 / 60.93 50.00
Vitamin E (mg) 5.20 / 3.7 5.00
Cholesterol (mg) 154.58 / 91.4 157.80
 
Table 3.6
Mean, standard deviation and median values for dry eye and dietary factors for 
females.
(N = 114)
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Figure 3.4
Mean OSDI values for males and females. 
Figure 3.3
Mean TMH values for males and females. 
Figure 3.2
NITBUT and TBUT mean timings for males and 
females.
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3.3.1 Subgroup analysis 
The difference between the independent sub-groups and the outcome measures was 
statistically assessed. According to the Kolmogorov-Smirnov statistic, none of the variables in the 
cohort were found to be normally distributed (significance value less than 0.05). For this reason 
The Mann-Whitney U Test was then used to investigate the difference in dry eye outcomes 
between the male and female independent groups. 
Using the Mann-Whitney U Test (significance value less than 0.05) there was a statistically 
significant difference in OSDI score. Females had statistically significant higher OSDI score 
(Z = −2.23, p = 0.03) with a small effect size using the Cohen (1988) criteria (r = 0.16). There was 
no statistically significant difference seen between the other dry eye outcomes and the two sub-
groups. There was no significant difference between age and smoking prevalence between the 
two gender groups. The results are shown in Table 3.7.  
Males Females
N
Mean /
Standard
Deviation
Median N
Mean / 
Standard 
Deviation
Median Z p
50 years and 
under 35 33.4 / 9.11 32 43 35.44 / 8.17 35 1.08 0.31
Over 50 years 51 71.55 / 10.74 71 71 68.89 / 10.15 67 -1.54 0.11
Smokers 8 51.25 / 20.35 46 7 49.14 / 12.90 47 -1.29 0.14
Non-smokers 78 56.51 / 21.53 60.5 107 56.74 / 19.09 61 1.14 0.22
OSDI score 86 21.65 / 21.22 16.67 114 25.77 / 18.96 16.67  – 2.23 0.03
TMH (mm) 86 0.39 / 0.13 0.40 114 0.38 / 0.14 0.40  – 1.08 0.28
NITBUT 
(seconds) 86 4.33 / 1.85 4.00 114 3.89 / 1.72 4.00  – 1.77 0.08
TBUT (seconds) 86 3.90 / 1.80 4.00 114 3.51 / 1.64 3.00  – 1.46 0.15
Total corneal 
staining 86 2.17 / 3.49 2.00  114 2.43 / 3.82 2.00  – 0.48 0.63
Total 
conjunctival 
staining
86 9.74 / 4.62 10.00  114 10.26 / 4.54 10.00  – 1.03 0.30
 
Table 3.7
Z and p values for relationships between gender and dry eye outcomes. 
43
3.4 Smokers and non-smokers subgroups
The cohort was divided into smokers and non-smokers subgroups for statistical analysis. The 
results showed there was a higher OSDI score for the smokers subgroup compared to non-
smokers. See Tables 3.8, below, and 3.9, next page, together with Figure 3.5, page 45.
Smokers Mean / 
Standard Deviation Median
Age (years) 50.27 / 16.7 50.00
Height (metres) 1.7 / 0.3 1.70
Weight (kg) 73.6 / 16.6 70.90
BMI 25.29 / 7.91 25.00
Vision (logmar) 0.80 / 0.30 0.80
VA (logmar) 0.11 / 0.16 0
NITBUT (seconds) 4.1 / 1.6 4.00
TMH (mm) 0.4 / 0.1 0.40
TBUT (seconds) 3.7 / 1.7 3.00
TOTAL corneal staining score 1.53 / 1.85 1.00
TOTAL conjunctival staining 
score 9.80 / 5.58 10.00
Total OSDI score 30.85 / 28.59 30.00
 Polyunsaturated fatty acids (g) 17.55 / 7.24 17.00
Energy (kcal) 1295.87 / 528.48 1273.00
Saturated Fat (g) 6.77 / 3.61 7.00
Carbohydrates (g) 70.26 / 64.98 70.00
Vitamin C (mg) 70.27 / 81.89 70.00
Vitamin E (mg) 4.83 / 3.32 5.00
Cholesterol (mg) 169.07 / 132.86 170.00
 
Table 3.8
Mean, standard deviation and median values for dry eye and dietary factors for the 
smokers sub-group.
(N = 15)
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Non-smokers Mean / 
Standard Deviation
Median
Age (years) 56.6 / 20.1 60.00
Height (metres) 1.7 / 0.2 1.70
Weight (kg) 70.5 / 14.4 70.90
BMI 25.03 / 7.48 24.10
Vision (logmar) 0.43 / 0.36 0.50
VA (logmar) 0.07 / 0.12 0
NITBUT (seconds) 4.1 / 1.9 4.00
TMH (mm) 0.4 / 0.1 0.30
TBUT (seconds) 3.7 / 1.7 3.00
TOTAL corneal staining score 2.38 / 3.78 2.00
TOTAL conjunctival staining score 10.06 / 4.50 10.00
Total OSDI score 23.44 / 19.13 16.67
Polyunsaturated fatty acids (g) 16.56 / 8.92 16.00
Energy (kcal) 1247.43 / 467.15 1273.00
Saturated Fat (g) 7.82 / 3.92 7.00
Carbohydrates (g) 58.84 / 37.83 58.00
Vitamin C (mg) 47.22 / 54.02 47.00
Vitamin E (mg) 5.24 / 3.62 5.00
Cholesterol (mg) 161.29 / 96.32 160.00
 
Table 3.9
Mean, standard deviation and median values for dry eye and dietary factors for the 
non-smokers sub-group.
(N = 185)
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3.4.1 Smokers and non-smokers
The difference between the independent sub-groups and the outcome measures was 
statistically assessed. According to the Kolmogorov-Smirnov statistic, none of the variables in the 
cohort were found to be normally distributed (significance value less than 0.05). For this reason 
The Mann-Whitney U Test was then used to investigate the difference between the smokers 
and non-smokers independent groups with the dry eye outcomes. There was no statistically 
significant difference in the dry eye outcomes between smokers and non-smokers. However, 
there was a statistically significant difference between the lifestyle habit of smoking and non-
smoking in both males and females, (Mann-Whitney U Test significance value less than 0.05). This 
significant difference would justify the following analysis on a reduced cohort to age and gender 
match in section 3.4.2. The results are shown in Table 3.10, next page. 
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Figure 3.5
Mean OSDI values for smokers and non-smokers.
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Smokers Non-smokers
N
Mean / 
Standard 
Deviation
Median N
Mean / 
Standard 
Deviation
Median Z p
Males 8 51.27 / 16.72 47 78 56.51 / 21.53 60.5 0.88 0.04
Females 7 49.14 / 12.90 47 107 56.74 / 19.09 61 0.76 0.03
50 years and 
under 70 34.19 / 8.82 33.5 8 37.5 / 6.16 36.5 0.34 0.67
Over 50 years 7 64.86 / 11.94 58 115 70.31 / 10.32 69 0.29 0.90
OSDI score 15 30.85 / 28.59 30.00 185 23.44 / 19.13 16.67  – 0.61 0.54
TMH (mm) 15 0.39 / 0.13 0.40 185 0.38 / 0.13 0.30  – 0.28 0.78
NITBUT 
(seconds) 15 4.13 / 1.55 4.00 185 4.08 / 1.81 4.00  – 0.46 0.65
TBUT (seconds) 15 3.67 / 1.68 3.00 185 3.68 / 1.73 3.00  – 0.10 0.92
Total corneal 
staining 15 1.53 / 1.85 1.00 185 2.38 / 3.78 2.00  – 0.31 0.76
Total 
conjunctival 
staining
15 9.80 / 5.58 10.00 185 10.06 / 4.50 10.00  – 0.60 0.56
Table 3.10
Z and p values for relationships between smokers, non-smokers and dry eye 
outcomes.
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3.4.2 Age and gender-matched smokers and non-smokers
The cohort was also separated into the sub-group of age and gender-matched smokers and 
non- smokers. As mentioned earlier, according to the Kolmogorov-Smirnov statistic, none of the 
variables in the cohort were found to be normally distributed (significance value less than 0.05). 
For this reason, The Mann-Whitney U Test was then used to investigate the difference between 
these two independent groups with the dry eye outcomes. As they were age matched, it was 
also statistically confirmed as there was no statistically significant difference in the ages  
(P = 0.98). There was also no statistically significant difference seen and in the dry eye outcomes 
between age and gender matched smokers and non- smokers. The results are shown in  
Table 3.11.
Smokers Non-smokers
N
Mean / 
Standard 
Deviation
Median N
Mean / 
Standard 
Deviation
Median Z p
Age 55.61 / 18.88 55.00 55.11 / 18.11 55.00  – 0.03 0.98
OSDI score 15 30.85 / 28.59 30.00 15 26.33 / 21.10 16.33  – 0.58 0.48
TMH (mm) 15 0.39 / 0.13 0.40 15 0.39 / 0.13 0.40  – 0.32 0.64
NITBUT 
(seconds) 15 4.13 / .55 4.00 15 4.01 / 1.62 4.00  – 0.54 0.69
TBUT (seconds) 15 3.67 / 1.68 3.00 15 3.69 / 1.71 3.00  – 0.11 0.88
Total corneal 
staining  15 1.53 / 1.85 1.00 15 2.16 / 3.66 2.00  – 0.28 0.71
Total 
conjunctival 
staining
15 9.80 / 5.58 10.00 15 10.11 / 4.33 10.00  – 0.48 0.51
Table 3.11
Z and p values for relationships between age and gender matched smokers, 
non-smokers and dry eye outcomes.
3.5 Summary
Of this sample of 200 participants, the mean OSDI score was 24 (median 17), which is well below 
the cut-off for diagnosis of DES. The proportion of participants with an OSDI score of over 30 was 
43%.
When comparing males and females, smokers and non-smokers, and those aged 50 years and 
below and those aged over 50 years, the only significant difference was that females had a 
significantly higher OSDI score than males (26 compared with 22). This gender difference is 
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supported by other studies highlighted in Chapter 1, which reported higher incidence of DES in 
perimenopausal women.10,13,14,16,17 
The fact that no difference was found between smokers and non-smokers is counter-intuitive, 
but could be explained by the fact that only 15 of the participant smoked. However, these results 
held even when the smoking participants were compared with a group of 15 age- and gender-
matched controls. 
There was no significant difference between the sub-categories for age. The participants who 
were aged 50 years and under when compared with the sub-group over the age of 50 years 
showed no statistical significance. This counter-intuitive result could be explained by the fact the 
average ages for the two categories were very similar.
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Chapter 4: The relationship between clinical methods of 
tear film evaluation
In the previous chapter, the baseline characteristics of the study cohort and subgroups were 
discussed. In this chapter, relationships that exist between the outcome measures will be 
explored. 
4.1 Background
Previous studies have reported correlations between different measures of tear analysis. For 
example, the tear stability in young Nigerian adults was measured using both TBUT and NIBUT. 
Forty five subjects aged 20 to 30 years were selected from among the students of University of 
Benin, Edo State. The TBUT values were comparable to the NIBUT values: these results showed 
that tear film stability can be confidently evaluated by either technique.89 
In another study the NITBUT was shown to be a more physiological method to assess tear film 
stability in patients with tear film disorders and the values measured by NITBUT were highly 
correlated with those measured by the TBUT.90
Correlation between OSDI and TBUT was explored when 68 patients admitted to the 
Ophthalmology Polyclinic of the Dumlupinar University in Turkey between December 2005 
and April 2006 were studied when evaluating the OSDI for the diagnosis of DES. The OSDI 
questionnaire was completed before the routine examination and then the TBUT test was 
carried out. There was a significant inverse correlation between the OSDI and TBUT test scores 
(r = − 0.296, p = 0.014). The conclusion was that OSDI is a standardised method which can easily 
be performed to evaluate symptoms to support the diagnosis of dry eye syndrome alongside 
tear tests such as TBUT.91
Similarly, the diagnostic values of the TBUT tests and OSDI in DES was assessed with thirty-five 
employees of the Istanbul Ümraniye Training and Research Hospital. All participants completed 
the OSDI. Following routine examination, the TBUT was undertaken and outcomes were 
compared. Investigators found that there was a significant inverse correlation between the OSDI 
and TBUT (r = − 0.385, p = 0.022). The researchers concluded that the OSDI questionnaire, used 
together with the TBUT, is an easily performed test and may be of benefit in supporting the 
diagnosis of DES.92
The other tear tests used in this study have been studied before to help improve predictive 
ability for the development of dry eye symptoms. Tear meniscus height and NIBUT were 
significantly, but moderately related to OSDI scores (r > 0.31, p < 0.05).93
4.2 Methods
As described in Chapter 2, the subjects were assessed by the researcher using clinical techniques 
found in routine optometric practice. 
4.3 Results
The baseline data were presented in tables in Chapter 3. 
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According to the Kolmogorov-Smirnov statistic, all the variables from the outcome measures 
were found not to be normally distributed (significance value less than 0.05). For this reason, a 
Spearman correlation was used to explore the strength of the relationships between them.
Analysis confirmed a statistically significant, weak negative correlation between OSDI scores and 
TBUT (rho = − 0.235, p = 0.001) and OSDI scores with NITBUT (rho = − 0.165, p = 0.02).  
NIBUT showed a strong positive correlation with TBUT (rho = 0.878, p = 0.0001) and a weak 
positive one with TMH (rho = 0.268, p = 0.0001). TMH showed a weak positive correlation with 
TBUT (rho = 0.225, p = 0.001). Results are seen as scatter plots in figures 4.1 to 4.5. 
Figure 4.1—Scatter plot showing a weak negative 
correlation between OSDI score and TBUT.
Figure 4.2—Scatter plot showing a weak negative 
correlation between OSDI score and NITBUT.
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Figure 4.5—Scatter plot showing a weak positive 
correlation between TMH and TBUT
Figure 4.4—Scatter plot showing a weak positive 
correlation between TMH and NITBUT.
Figure 4.3—Scatter plot showing a strong positive 
correlation between TBUT and NITBUT.
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4.4 Logistic Regression
Of the 200 subjects of this study, 85 had an OSDI score of over 30 and were therefore diagnosed 
as having dry eye syndrome.
The data was transformed and a logistic regression was performed to see which of the different 
clinical parameters best predict severe dry eye as diagnosed using the OSDI score (over 30). The 
model contained two independent variables (TBUT and NITBUT). The full model containing these 
two predictors was statistically significant χ 2 (2, N = 2 00) = 69.10, p < 0.001.
The strongest predictor of dry eye was TBUT, recording an odds ratio of 8.11. This indicated that 
respondents who had a TBUT of less than 5 seconds were over 8 times more likely to suffer from 
dry eye syndrome than respondents with a TBUT greater than 5 seconds. 
4.5 Summary
The negative correlations between OSDI scores and TBUT revealed a rho = − 0.235 and p = 0.001 
demonstrating a weak strength of correlation. TBUT was also the strongest predictor of dry eye 
(OSDI score over 30). This was consistent with findings in another study.92 In comparison, the 
negative correlation between OSDI score and NITBUT was weaker showing  
rho = − 0.165, p = 0.02. Again, this was a similar finding to that from a previous study. 93 
As found in other studies,89,90 NITBUT was found to correlate well with TBUT with a strong 
positive correlation (rho = 0.878, p < 0.001): suggesting that tear film stability can be confidently 
evaluated by either of the techniques and therefore confirming that alongside the OSDI score 
NITBUT can easily be performed to evaluate symptoms to support the diagnosis of dry eye 
syndrome. 
This study shows that TMH correlated significantly and similarly with both NITBUT and TBUT. 
Although there was an inverse correlation between TMH and OSDI score, this was not statistically 
significant. Other studies have found a statistically significant, but moderate, correlation 
between TMH and OSDI.93 The key findings in this chapter are consistent with other studies, in 
particular studies where Pult et al93 and Ozcura et al91 concluded that deriving an OSDI score 
should be a standardised procedure to evaluate symptoms of and support the diagnosis and 
correlation with dry eye syndrome.90,91,92,93 TBUT was the best predictor of dry eye syndrome, 
although as found in previous studies,91,92 the low agreement found between subjective 
symptoms and objective tests reflects difficulties in making a diagnosis of dry eye as although 
the parameters are statistically shown to be related, the correlation is not perfect therefore 
suggesting there is a need to perform both objective and subjective tests because they provide 
different information.
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Chapter 5: Analysis of relationships between tear film analysis and diet
5.1 Non-parametric statistical analysis
According to the Kolmogorov-Smirnov statistic, all the variables were found not to be normally 
distributed (significance value less than 0.05). For this reason, Spearman correlation was used to 
explore the strength of the relationship between the outcome measures of dry eye disease and 
dietary factors extracted from the dietary software. 
The following nutritional dietary factors were extracted from the a la calc software as they these 
nutrients have been linked with DES in previous studies, as discussed in Chapter 1.
Polyunsaturated fatty acids (PUFAs encompassing EFAs)
Carbohydrates
Vitamin C
Vitamin E
Cholesterol
Calories
Saturated fat
Statistical analysis on the whole group concluded that high OSDI scores were significantly 
associated with lower consumption of polyunsaturated fatty acids showing a weak positive 
correlation (rho = 0.21, p < 0.001), a weak negative correlation with carbohydrate intake  
(rho = − 0.25, p < 0.001), cholesterol intake (rho = − 0.16, p = 0.03),  
calories (rho = − 0.33, p < 0.001) and saturated fat intake (rho = − 0.16, p = 0.03).  
Greater TMH was associated with higher consumption of cholesterol showing a weak positive 
correlation (rho = 0.18, p = 0.01). Results are seen in scatter plots Figures 5.1 to 5.5.
Figure 5.1—Scatter plot showing a weak negative 
correlation between PUFA intake and OSDI score.
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Figure 5.2—Scatter plot showing a weak negative 
correlation between carbohydrate intake and OSDI 
score.
Figure 5.3—Scatter plot showing a weak negative 
correlation between cholesterol intake and OSDI score.
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5.2 Logistic Regression
The data was transformed and a logistic regression was performed to see which of the different 
dietary factors best predict an OSDI score of less than 30, and therefore not suffering from dry 
eye syndrome. The model contained seven independent variables (PUFA encompassing EFA, 
Figure 5.4—Scatter plot showing relationship between 
calorie intake and OSDI.
Figure 5.5—Scatter plot showing a weak positive 
correlation between cholesterol intake and TMH.
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carbohydrates, vitamin C, vitamin E, cholesterol, calories and saturated fat). The full model 
containing these seven predictors was statistically significant Χ2 (7, N = 200) = 71.42, p < 0.001. 
The strongest predictors of not suffering from dry eye were PUFA intake recording an odds ratio 
of 7.91. This indicated that subjects who had consumed PUFAs in their diet were over 7 times 
more likely to be not suffering from dry eye syndrome. Carbohydrate had an odds ratio of 8.01 
and calorie intake had an odds ratio of 8.51 and therefore both were over 8 times more likely to 
predict not suffering from dry eye syndrome. When investigating relationships it is important to 
control for confounders, and potential confounders were identified to be smoking and contact 
lens wear. Therefore, the relationships between signs and symptoms of DES were re-analysed 
within subgroups of the cohort.
5.3 Non-smokers
The data was controlled for smokers. The sub-group of non-smokers was analysed and it was 
found that high OSDI scores were significantly associated with lower consumption of PUFA, 
showing a weak negative correlation (rho = − 0.24, p < 0.001),  
carbohydrate (rho = − 0.21, p = 0.004), cholesterol (rho = − 0.13, p = 0.04),  
calories (rho = − 0.33, p < 0.001) and saturated fat (rho = − 0.16, p = 0.04).  
Greater TMH was associated with higher consumption of cholesterol showing a weak positive 
correlation (rho = 0.17, p = 0.02). Scatter plots 5.6 and 5.7 illustrate the stronger relationships. 
Figure 5.6—Scatter plot showing a weak negative 
correlation between PUFA intake and OSDI score in non-
smokers.
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5.4 Non-contact lens wearers
The data was controlled for contact lens wear. The non-wearer sub-group was analysed and 
revealed that high OSDI scores were significantly associated with lower consumption of  
PUFA (rho = − 0.20, p = 0.01), carbohydrate (rho= − 0.25, p < 0.001),  
cholesterol (rho = − 0.15, p = 0.03), calories (rho= − 0.31, p < 0.001) and  
saturated fat (rho = − 0.16, p = 0.03), all showing a weak negative correlation. Greater TMH was 
associated with higher consumption of cholesterol (rho = 0.19, p = 0.01). See Figure 5.8, below, 
for the results. 
Figure 5.7—Scatter plot showing relationship between 
calorie intake and OSDI score in non-contact lens 
wearers
Figure 5.8—Scatter plot showing a weak negative 
correlation between carbohydrate intake and OSDI 
score in non-contact lens wearers
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5.5 Bonferroni correction
A Bonferroni correction was used to reduce the chances of obtaining false-positive results. As 
there were thirty-five hypotheses being tested, the adjusted p value was calculated  
to be 0.001 (0.05/35). This correction was applied to the original results from the whole group 
and the two sub-groups. 
Analysis on the whole group revealed that high OSDI scores were found to be significantly 
associated with lower consumption of PUFA (rho = − 0.21, p < 0.001), carbohydrate 
(rho = − 0.25, p < 0.001) and calories (rho = − 0.33, p < 0.001) even with this adjusted p value, all 
showing a weak negative correlation. See Table 5.1 for results. 
 Polyunsaturated fatty acids
N Mean / Standard Deviation rho p
OSDI score 200 24.00 / 20.01  – 0.21 <0.001
 Carbohydrates
N Mean / Standard Deviation rho p
OSDI score 200 24.00 / 20.01  – 0.25 <0.001
Calories
N Mean / Standard Deviation rho p
OSDI score 200 24.00 / 20.01  – 0.33 <0.001
Table 5.1
N, rho and p values for all analyses on the whole group after applying a Bonferroni 
correction. Only significant relationships are shown.
5.5.1 Non-smokers
Analysis on the non-smokers revealed there to be a statistically significant relationships 
even with the adjusted p value. High OSDI scores were significantly associated with lower 
consumption of PUFA (rho = − 0.24, p < 0.001) and calories (rho = − 0.33, p < 0.001) with a weak 
negative correlation seen. See Table 5.2.
 Polyunsaturated fatty acids
N Mean / Standard Deviation rho p
OSDI score 185 23.43 / 19.13  − 0.24 <0.001
Calories
N Mean / Standard Deviation rho p
OSDI score 185 23.43 / 19.13  − 0.33 <0.001
Table 5.2
N, rho and p values for the analyses for the non-smokers sub-group after applying 
a Bonferroni correction. Only significant relationships are shown.
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5.5.2 Non-contact lens wearers
Analysis on the non-contact lens wearing sub-group revealed there to be a statistically 
significant relationships after the Bonferroni correction. High OSDI scores were significantly 
associated with lower consumption of carbohydrate (rho = − 0.25, p < 0.001) and  
calories (rho = − 0.31, p < 0.001), both showing a weak negative correlation. See Table 5.3, below.
 Carbohydrates
N Mean / Standard Deviation rho p
OSDI score 183 24.51 / 19.96  − 0.25 <0.001
Calories
N Mean / Standard Deviation rho p
OSDI score 183 24.51 / 9.96  − 0.31 <0.001
Table 5.3
N, rho and p values for analyses for the non-contact lens sub-group after applying 
a Bonferroni correction. Only significant relationships are shown.
The limitations of this software include inability to extract omega-3 or omega-6 nutrient values 
from polyunsaturated fatty acids. To compensate for this, it was noted if the subject had recorded 
in their food diaries the consumption of at least one portion of oily fish or nuts. 
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5.5.3  Oily fish
The Mann-Whitney U Test was used to investigate the difference in dry-eye outcome measures 
between those subjects who had consumed at least one portion of oily fish and those who had 
not. The UK National Health Service advises that a single portion of oily fish may be defined as 
about 140g, after cooking.132
There was a significant difference in TMH: those who did consume oily fish had a significantly 
higher TMH (Z = − 2.23, p = 0.026) than those who did not. There was also a counterintuitive 
higher mean OSDI score amongst those who consumed oily fish compared with those that did 
not (Z = − 2.079, p = 0.038). The results are shown in Table 5.4, below. 
Consumed oily fish Did not consume oily fish
N
Mean / 
Standard 
Deviation
N
Mean / 
Standard 
Deviation
Z p
OSDI score 88 26.34 / 18.98 112 22.10 / 0.71  – 2.079 0.038
TMH (mm) 88 0.41 / 0.12 112 0.37 / 0.14  − 2.23 0.026
NITBUT (seconds) 88 4.24 / 1.95 112 3.95 / 1.64  − 0.016 0.987
TBUT (seconds) 88 4.06 / 2.05 112 3.35 / 1.28  − 1.168 0.243
Total corneal 
staining 88 2.00 / 2.54 112 2.57 / 4.36  − 0.063 0.950
Total conjunctival 
staining 88 10.48 / 4.26 112 9.70 / 4.80   − 1.598 0.110
Table 5.4
Z and p values for relationships between dry eye outcomes and consumption of at 
least one portion of oily fish.
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5.5.4  Nuts
The Mann-Whitney U Test was used to investigate the difference in dry-eye outcome measures 
between those subjects who had consumed at least one portion of nuts and those who had 
not. The UK National Health Service advises that a single portion of nuts may be defined as 
approximately one ounce, or 28g, which is about as much as will fit in the palm of a hand.132 
The results showed that those consuming nuts had a significantly lower OSDI score 
(Z = − 4.018, p < 0.001), higher TMH (Z = −2.867, p = 0.004), and longer NITBUT 
(Z = −3.616, p < 0.001) and TBUT (Z = − 4.174, p < 0.001) than those that did not.  
The results are shown in Table 5.5, below.
Consumed nuts Did not consume nuts
N
Mean / 
Standard 
Deviation
N
Mean / 
Standard 
Deviation
Z p
OSDI score 114 18.69 / 15.42 86 31.40 / 23.17  − 4.018 <0.001
TMH (mm) 114 0.41 / 0.13 86 0.35 / 0.13  − 2.867 0.004
NITBUT (seconds) 114 4.42 / 1.75 86 3.65 / .75  − 3.616 <0.001
TBUT (seconds) 114 4.13 / 1.81 86 3.10 / 1.40  − 4.174 <0.001
Total corneal 
staining 114 1.93 / 2.77 86 2.84 / 4.57  − 1.420 0.156
Total conjunctival 
staining 114 9.72 / 4.29 86 10.47 / 4.92   – 1.397 0.162
Table 5.5
Z and p values for relationships between dry eye outcomes and consumption of at 
least one portion of nuts.
5.6  Summary
Statistical analysis on the whole group concluded that high OSDI scores were significantly 
associated with lower consumption of PUFAs, carbohydrate, cholesterol, calories and saturated 
fat. After the Bonferroni correction was applied with the adjusted p value, analysis confirmed 
higher OSDI scores were significantly associated with lower consumption of PUFAs, carbohydrate 
and calories. 
Both the non-smokers and non contact lens wearing sub-groups revealed high OSDI scores 
significantly associated with lower consumption of PUFAs carbohydrate, cholesterol, calories and 
saturated fat. Further analysis after the Bonferroni correction confirmed that high OSDI scores 
were significantly associated with lower consumption of PUFAs and calories in the non-smokers 
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sub-group and with lower consumption of carbohydrates and calories in the non contact lens 
wearing sub-group.
Greater TMH was seen in subjects who had higher consumption of cholesterol. This applied also 
when controlling for smoking and contact lens wear. There was also a significant difference in 
TMH in those who consumed nuts and oily fish as had a significantly higher TMH than those who 
did not. Also, results showed that those consuming nuts had a significantly lower OSDI score, 
together with increased NITBUT and TBUT, than those who did not. 
There was also a counterintuitive higher mean OSDI score among those who consumed oily fish 
compared with those who did not.
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Chapter 6: Intra-practitioner reliability 
of outcome measures
Intra-practitioner reliability of the outcome measures was explored: this entailed inviting 
58 participants to return to the practice to be reassessed by the researcher using the same 
techniques as before (described in Chapter 2). 
6.1 Results from repeated assessments
According to the Kolmogorov-Smirnov statistic, all variables from the original 200 subjects  
and the repeated 58 were not found to be normally distributed (significance value less than 
0.05). 
After measurements had been repeated on the 58 subjects, it was important to assess for 
each of them the level of agreement between the initial and second sets of measurements—
any discrepancies needed to be evaluated to see how significant they were. Therefore, the 
differences between the clinical outcome measurements from the two visits were related to the 
mean and a log transform was performed. The mean and standard deviation of the differences 
were calculated. The mean difference should be zero since the same method of measurement 
was used. If the mean difference is significantly different from zero, it will not be possible to use 
the data further because one or both of the two sets of measurements might not reflect the true 
situation—due to measurement errors, changes in the subject’s circumstances, and so on. The 
definition of a repeatability coefficient adopted by the British Standards Institution requires that 
95% of differences should be less than two standard deviations.128
It was determined whether there was a difference between each set of two measurements and 
how they varied from one another. A one-sample t-test was conducted with the null hypothesis 
that there is zero difference between the two measurements and that they completely agree.  
The t-test on the results from the OSDI score outcome measures revealed significance value 
of less than 0.05 between the two visits (mean difference = − 9.48879 and p-value was 0.000). 
Hence, this was regarded as significantly different from one visit to the other. This result did not 
show a useful level of agreement and therefore Bland-Altman analysis was not conducted. All 
other clinical outcome measures revealed a significance value of greater than 0.05, confirming 
that the measurements from the two separate visits were not significantly different from one 
another (p-value >0.05). For these clinical measures, a Bland-Altman analysis was used to assess 
the level of agreement of the outcome measures between the two visits. The mean difference 
between each set of two measurements was determined to see if they differed significantly from 
zero and therefore to check if there was a resultant bias. Linear regression was carried out to 
confirm or reject the null hypothesis that the coefficient for mean is zero.
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The Bland-Altman analysis on NITBUT clinical measure on the two occasions indicated a mean 
difference of 0.0517 with 95% limits of agreement between the two visits and measurements 
ranged from − 0.0519 to 0.1553. Linear regression was carried out to confirm or reject the null 
hypothesis that the coefficient for mean is zero. In this instance, the beta value was 0.0171 and 
did not reveal a statistically significant result as p = 0.585: therefore it was concluded that there 
was no proportional bias and confirmed that there was no trend showing more data points 
above or below the mean score. See Figure 6.1, above.
The Bland-Altman analysis on TBUT clinical measure on the two occasions indicated a mean 
difference of − 0.2414 with 95% limits of agreement between the two visits and measurements 
ranged from − 0.4521 to 0.0306. Linear regression was carried out to confirm or reject the null 
hypothesis that the coefficient for mean is zero. In this instance, beta value was − 0.171 and 
revealed a statistically significant result as p = 0.004: therefore there was a proportional bias as 
seen in Figure 6.2 with a cluster of data points below the mean score. See Figure 6.2, above.
 Fig 6.1—Bland-Altman plot, NITBUT.
Figure 6.2—Bland-Altman plot, TBUT.
65
The Bland-Altman analysis on TMH clinical measures on the two occasions indicated a mean 
difference of 0.0052 with 95% limits of agreement between the two visits and measurements 
ranged from − 0.0154 to 0.0257. Linear regression was carried out to confirm or reject the null 
hypothesis that the coefficient for mean is zero. In this instance beta value was 0.095 and did not 
reveal a statistically significant result as p = 0.266: therefore there was no proportional bias and 
that there was no trend showing more data points above or below the mean score.  
See Figure 6.3, above.
The Bland-Altman analysis on corneal staining indicated that there is mean difference of − 
0.0517 with 95% limits of agreement between the two visits and measurements ranged from 
− 0.1175 to 0.0140. Linear regression was carried out to confirm or reject the null hypothesis 
that the coefficient for mean is zero. In this instance beta value was 0.082 and did not reveal a 
statistically significant result as p = 0.053: it was concluded that there was no proportional bias 
and that there was no trend showing more data points above or below the mean score.  
See Figure 6.4, above.
Figure 6.3—Bland-Altman plot, TMH.
Fig 6.4—Bland-Altman plot, corneal staining.
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The Bland-Altman analysis on conjunctival staining indicated that there is mean difference of 
0.0329 with 95% limits of agreement between the two visits and measurements ranged from 
− 0.0642 to 0.1300. Linear regression was carried out to confirm or reject the null hypothesis 
that the coefficient for mean is zero. In this instance, beta value was 0.134 and did not reveal a 
statistically significant result as p = 0.079 therefore it was concluded there was no proportional 
bias and that there was no trend showing more data points above or below the mean score.  
See Figure 6.5, above.
6.2 Summary
The Bland-Altman analysis on clinical measurements of TBUT, NIBUT, TMH and corneal and 
conjunctival staining on the two occasions showed there was no proportional bias and 
confirmed there was no trend showing more data points above or below the mean score and 
therefore there was consistency in intra-practitioner repeatability. These clinical measurements 
can vary and consistency of interpretation is key as other studies have found that clinical 
outcome measurements were highly variable under all conditions130,131
The t-test on the results from the OSDI score outcome measures revealed significance value 
of less than 0.05 between the two visits. Hence, this was regarded as significantly different 
from one visit to the other. This did not show a useful level of agreement and is an example of 
patient-reported symptoms which can be only moderately repeatable from visit to visit, and thus 
confirmed that procedures clinically used to diagnose and monitor dry eye syndromes can in this 
case be regarded as unrepeatable.129
Fig 6.5—Bland-Altman plot, conjunctival staining.
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Chapter 7: Discussions and Conclusions
Every eye care professional and optometrist will encounter patients who present with the overt 
symptoms of dry eyes—such patients complain of ‘soreness’, ‘dryness’, ‘grittiness’ and other 
sources of discomfort. However, the degradation of ocular optical qualities resulting from DES 
often results in patients presenting to their optometrist with visual impairments they have 
noticed during critical tasks such as driving or viewing a computer screen, phone, or tablet. 
These impairments result from changes in aberration caused by changes in tear film.72 
Symptoms of dry eye can be treated with moderate success, but long term solutions are needed 
both to prevent its occurrence and to ameliorate the symptoms more effectively when it does 
occur.
The aim of the present study was to investigate the relationship between diet and clinical 
assessment of the tear film in routine optometric practice and add to existing studies. Dry eye 
syndrome is widespread in the population, and, although not sight-threatening, it can reduce 
quality of life. For this reason alone, research into DES is well worthwhile, and one approach has 
been to investigate the possible relationship between diet and DES. A number of studies have 
been conducted in various parts of the world but few studies and little data are available for the 
UK.10,13,15,16,17,18,20,29,43,44,45,59,50,52,64,80,89,90,91,94,95,96,101,112,113, 115,116 
The a la calc nutritional software used in this study is new, having been established just under 
five years ago. It has its limitations, but the alternatives had greater limitations and showed no 
improvements. The inability of a la calc to separate omega-3 and omega-6 EFA’s was a major 
disadvantage and essentially a flaw: this study attempted to overcome that aspect by having the 
consumption of nuts and oily fish recorded in patients’ food diaries. It would have been valuable 
to assess blood serum levels of nutrients but this was not possible due to the optometric 
practice-based nature of the research.
There are a number of techniques that can be used for tear film assessment in routine 
optometric practice, but it is it is impractical to conduct every test on every patient. The clinical 
outcome measures used in this study were chosen as they were readily available in optometric 
practice and representative of the tests readily conducted by optometrists. 
The tear film is inherently variable during the day and unfortunately this remained a flaw for 
this study as tear film evaluations were carried out on various days and times of day. All the 
subjects were recruited from only one practice and this resulted in another major limitation. 
Also, the average age of the subjects recruited in this study was 56 years with larger proportions 
of females and non smokers than males and smokers. Furthermore, these demographics were 
not representative of the UK as all the subjects were Caucasian and comparisons could not be 
made between different ethnicities. To overcome this deficiency, further research would need 
to be conducted in various locations more representative of the UK population as regards 
ethnicity, age and lifestyle habits. This is especially important as it has been confirmed that DES 
can be significantly associated with environment and ethnicity,138,148,149 For example, in Japan, 
prevalence of DES has been recorded as high as 33%.136 
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The present study consisted of 200 participants: the mean OSDI score was 24 (median 17), 
which is well below the cut-off for diagnosis of DES. The percentage of participants with an OSDI 
score of over 30 was 43%. When comparing the subgroups, the only significant finding revealed 
that females had a significantly higher OSDI score than males (26 compared with 22). Females 
also revealed dry eye outcomes such as lower TBUT, NITBUT and TMH compared with males. 
This is also consistent with previous research sources1,10,13,14,16,17,134 and in more recent 
studies conducted in the United States with two large cross-sectional surveys, the Women’s 
Health Study and the Physician’s Health Studies, demonstrating that the prevalence of dry eye 
or severe dry eye symptoms was 7.8% in women and 4.3% in men aged 50 years and older. 
Sixteen larger studies have reconfirmed a link between being female and having a higher risk of 
DES.10,14 Within the 25,665 postmenopausal women in the Women’s Health Study, a significant 
association was made with an increased risk of clinically diagnosed dry eye syndrome and severe 
symptoms.16 
Increasing age and the prevalence of dry eye syndrome is a well known association both in males 
and females.1,10,16,17,94 However, in this study, there was no significant difference between the 
sub-categories for age when comparing those participants who were aged 50 years and under 
with the sub-group over the age of 50 years. This counter-intuitive result could be explained by 
the fact that the average ages for the two categories were very similar (the result was reflective 
of the patient base and general catchment of the research location). A more diverse age range 
would be required to fully understand the overall relationship between increasing age and DES.
Statistical analysis on the whole group concluded that high OSDI scores were significantly 
associated with lower consumption of polyunsaturated fatty acids and there was a weak 
negative correlation with the intake of carbohydrate, cholesterol, calories and saturated fat. 
This is consistent with studies mentioned earlier.25,27,32, 33,34,35 After controlling for contact 
lens wear and smoking and after applying the Bonferroni correction with the adjusted p value, 
analysis confirmed higher OSDI scores were significantly associated with lower consumption 
of PUFAs. This is consistent with findings by other researchers,139,140 However, the inverse 
relationship seen between OSDI score and the intake of carbohydrate and calories is a new 
finding and one which will merit further investigation. Greater TMH was seen in participants 
who had higher consumption of cholesterol. This applied also when controlling for smoking and 
contact lens wear. There was also a significant difference in TMH in participants who consumed 
nuts and oily fish as these persons had a significantly higher TMH than those who did not. Also, 
results showed that those consuming nuts had a significantly lower OSDI score, together with 
increased NITBUT and TBUT, than those who did not.
Objectively correlating changes in dry eye syndrome with blood levels of omega-3 EFAs has not 
been done in a large-scale multisite study. There is also no consensus on the dose, composition, 
length of treatment, and so on, with omega-3 or omega-6 EFAs. Increased quality evidence 
on the usefulness of over-the-counter supplements is needed to enable doctors and eye care 
practitioners to confidently outline specific treatment recommendations for using omega-3 
EFAs in DES.98 Indeed, a comparative study in India demonstrated the beneficial effect of orally 
administered omega-3 EFAs in alleviating dry eye symptoms, decreasing tear evaporation rate 
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and improving symptoms in patients suffering dry eye related to computer vision syndrome.99 
The use of EFAs in dry eye needs to be further investigated, particularly as EFAs have already 
shown their usefulness in systemic conditions.
The key to understanding the potential benefits of EFAs is to gain a clearer understanding 
of their physiological interactions and to ensure that appropriate amounts of each EFAs are 
consumed. Individuals with dry eye often seek advice from doctors and eye care practitioners 
such as optometrists: these professionals should familiarise themselves with EFAs and their 
benefits and recommend to patients that they increase their consumption of omega-3 EFAs to 
help alleviate the symptoms. Increasing consumption of oily fish helps to reduce DES symptoms 
and full spectrum multi-vitamin/mineral/EFA nutritional supplements provide the opportunity to 
optimise dietary defences against DES.150 Future studies in patient-reported outcome measures 
for dry eye and ocular surface disease should address these issues.
Although this study revealed no statistically significant difference in dry eye outcome measures 
between smokers and non-smokers, it has also been recorded that various lifestyle habits such 
as smoking can cause adverse effects on the precorneal tear film with a strong association 
between smoking and tear film instability.133,134,135 As mentioned earlier, it is well known 
that smoking can cause adverse effects on the tear film as seen in much larger studies where 
more of participants examined had significant smoking habits.134,135 Future directions for this 
study should explore the current effect of shisha and E-cigarettes. Although relatively scarce, 
the existing data with regards to DES and socioeconomic background and lifestyle habits does 
suggest a substantial link.140,141,142,143,144 Future aspects of study should include other factors 
such as mental health and general well-being and fitness. This has been briefly explored with 
research into the association of DES with anxiety and depression which has shown a positive 
association and would be of clinical relevance.145,146,147
This study was carried out on a population of 200 subjects drawn from patients of an optometric 
practice located in the east of the United Kingdom, resulting on a cohort not representative 
of the general population of the UK. Nevertheless, the results have suggested further areas for 
research including investigation of the inverse relationship found between OSDI score and the 
intake of PUFAs, carbohydrate and calories.
The results and information from the present thesis reinforce suggestions that optometrists 
and medical professionals such as family doctors would be well placed not only to treat the 
symptoms of DES by prescribing lubricating eye drops or tear substitutes but should also be 
more aware of the effects of dietary intake on DES and the possibility of ameliorating symptoms 
by suggesting changes to the patient’s diet. No doubt further research by others will clarify how 
best to use changes in diet in the treatment of DES.
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APPENDICES
Appendix 1
Ethical approval 
Aston Triangle 
Birmingham B4 7ET 
United Kingdom 
Tel +44 (0)121 204 3000 
www.aston.ac.uk  
Memo 
Life and Health Sciences Research Ethics Committee’s Decision Letter 
The documentation and additional information for the above proposal has been considered by the Chair of 
the LHS Research Ethics Committee.  
Please see below for details of the decision and the approved documents: 
Reviewer’s recommendation: Approved. 
Reviewer’s comments:  This study may now proceed. 
Please see the tabled list below of approved documents: 
Documentation Version/s Approved
Consent Form 1 √
Participant Information Sheet (PIS) 1 √
Protocol 1 √
Risk Assessment N/A 
Questionnaires 1 √
Other (please detail):   
To :  Dr  Hannah Bartlett 
Cc: Rachel Moorhouse, administrator to the Life and Health Sciences Research Ethics Committee 
From: Dr Doina Gherghel 
Chair of the Life and Health Sciences Research Ethics Committee  
Date: 11/07/2012 
Subject: Project : # 367.  
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The study has been approved by the Aston University Human Sciences Ethical Committee on 11th July 2012 – ethics 
application number 367.
Because of ethical issues raised by the design of this protocol the inconvenience in attending and carrying out any ad-
ditional tests, recording of data relating to results obtained from participants and risks associated with questionnaires, 
it is necessary to put the following additional protections in place for the research participants:
Anonymity
This will be preserved by the removal of identifiers and the use of ID numbers or pseudonyms, breaking the link be-
tween data and identifiable individuals. 
Risks and benefits
There is no known physical or psychological risk. Patients may gain benefits from this study in relation to dry eye and 
their diet.
Informed consent
Verbal and signed written informed consent will be obtained for participation.
Voluntary Participation
Participation will be voluntary; participants will not be coerced into participating by offering incentives to do so. Partici-
pants may withdraw from taking part at any point. 
Privacy and confidentiality
Responses to questionnaires and tear film analysis will be confidential. Presentation of the results will omit any fac-
tor which personally identifies the participant, therefore, maintaining confidentiality. All data and questionnaires will 
be kept in a locked drawer unless being processed. When input on to a computer the information will be stored on a 
password-protected PC. The data will be analysed in a private study area by the chief investigator.
By instituting these additional protections, any risks have been appropriately minimised, and a reasonable and ethically 
acceptable balance between risks and benefits has been established. 
After starting your research please notify the LHS Research Ethics Committee of any of the 
following at; lhs_ethics@aston.ac.uk  
Please quote the original project reference number with all further correspondence. 
• Substantial amendments – Any amendment should be sent as a Word document, with the amendment 
highlighted.  
Please include a version number and amended date to the file name of any amended documentation (e.g. 
Ethics Application #100 Protocol v2 amended 17/02/12) - When any amendments are submitted they need 
to be accompanied by new protocols / PIS etc. as necessary, with the new version numbers included.  
• New Investigators 
• The End of the Study 
 
All necessary documents are available to download from; http://www.ethics.aston.ac.uk/documents-all  
Please note that these documents can ONLY be opened using Mozilla Firefox or the latest Internet Explorer 
version (IE9). 
Statement of Compliance 
The Committee is constituted in accordance with the Government Arrangements for Research Ethics 
Committees (July 2001) and complies fully with the Standard Operating Procedures for Research Ethics 
Committees in the UK. 
Yours sincerely 
Dr Doina Gherghel 
Chair of the LHS Research Ethics Committee 
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Appendix 2
Subject Information sheet and consent form
Research workers, school and subject area responsible
Optometrist Researcher: 
Sheeraz Janjua BSc(HONS) DipSv MCOptom MIoD
Project Title
The relationship between diet and dry eye syndrome
Invitation
You are being invited to take part in a research study. Before you decide it is important for 
you to understand why the research is being done and what it will involve. Please take time 
to read the following information carefully. 
What is the purpose of the study? 
Dry eye is a common condition, increasing with age. Current treatments deal with the man-
agement of the tear film. Relief may be achieved through instillation of artificial tears, although 
this does not last long because these topical treatments generally treat the symptoms and 
are unable to resolve the underlying cause. Large prevalence studies and studies relating 
dietary intake with dry eye have been conducted in other parts of the world; however, little 
data is available for the UK. There is evidence to suggest that certain dietary constituents, 
such as essential fatty acids (EFA), particularly omega-3 EFA, may be effective in dealing 
with the underlying causes and reduce the risk for dry eye. This relationship can be explored 
in detail using food diaries, dry eye questionnaires and tear analysis.
What will happen to me if I take part?
This research will involve patients from research centres and optometry clinics based in the 
UK. Participation will involve a single visit to one of the centres or clinics.
You will be asked to:
•	 Answer a 24 hour food recall questionnaire
•	 Complete a health and lifestyle questionnaire
•	 Complete a dry eye questionnaire
•	 Consent to having your tear layer assessed by the researcher using standard opto-
metric techniques
Are there any potential risks in talking part in the study?
There is no known psychological risk. Physical risks include a minimal, brief, discoloration 
of the eye and the possibility of a corneal abrasion. This risk will be minimised by giving you 
accurate instructions when the researcher performs the tests.
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All data will remain anonymous at all times. Data analysis will be carried out by clinicians 
and statisticians. Any other members of the research team will only be given access to the 
database after your identity has been removed. 
Do I have to take part?
No, you do not have to participate if you do not wish to do so. You are free to withdraw at any 
time from the project without any penalty. 
Expenses and payments:
There are no expenses or payments for participation in this project.
Will my taking part in this study be kept confidential?
Yes, your participation in the study will be fully confidential. There will be no way to link any 
research data to any individual participant. All data will be anonymised.
What will happen to the results of the research study?
We aim to publish the results of this project. However, there will be no direct reference to any 
individual’s data in any publication. 
Who is organising and funding the research?
The researcher is organising the study. There is no funding for this research project.
Who has reviewed the study?
The research has been submitted for approval by Aston University’s Life and Health Sci-
ences Research Ethics Committee.
Who do I contact if something goes wrong or I need further information? 
Please feel free to contact the chief researcher: Mr Sheeraz Janjua (janjuasa@aston.ac.uk)
Who do I contact if I wish to make a complaint about the way in which the research 
is conducted? 
If you have any concerns about the way in which the study has been conducted, then you 
should contact Aston University’s Life and Health Sciences Research Ethics Committee on 
j.g.walter@aston.ac.uk or telephone 0121 204 4665. 
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Study Number:
Patient Identification Number:
VOLUNTEER CONSENT FORM
Title of Project: The relationship between dietary intake and dry eye.
Name of Chief Researcher: Mr. Sheeraz Janjua BSc (Hons) DipSv MCOptom MIoD
Please tick box
1. I confirm that I have read and understand the information sheet for the above study. I 
have had the opportunity to consider the information, ask questions and have had these 
answered satisfactorily.  
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason, without my medical care or legal rights being affected.  

3. I agree to take part in the above study. 
________________________ ____________________________________
Name of Patient Date Signature
_________________________ ____________________________________
Name of Person taking consent Date Signature
(If different from Researcher)
_________________________ ____________________________________
 Researcher Date             Signature
When completed, 1 copy for patient; 1 copy for researcher file.
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Appendix 3
Advertisement for recruitment of subjects
Scunthorpe Telegraph
People needed for eye research
There is increasing evidence to suggest that certain dietary 
constituents, such as essential fatty acids, reduce the risk of Dry Eye 
Syndrome.
This relationship will be explored using food diaries, dry eye 
questionnaires and tear analysis by Optometrist at O’Briens Opticians 
in Brigg – Sheeraz Janjua (pictured).
Mr Janjua is currently studying for a Doctor of Optometry Postgraduate 
qualification at Aston University and is seeking to assess people who 
suffer from Dry Eye Syndrome as part of his research thesis.
People interested in participating should contact the practice on 01652 
653595.
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Appendix 4
INDES Health and lifestyle questionnaire
Study Number:
Unique ID (Patient Identification Number)
1. _________________ 
2.  Male/Female ___________ 
3. Date of Birth ___________ 
4. What is your ethnic background? (circle those which apply)
•	 Asian or Asian British – Bangladeshi/Indian/Pakistani
•	 Black or black British – African/Caribbean
•	 Chinese 
•	 Mixed – white and Asian/White and black African/ White and black Ca-
ribbean
•	 Other Asian (please state) ________________________
•	 Other Black (please state) ________________________
•	 Other mixed (please state) ________________________
•	 White – British/Irish
•	 Other white (please state)_________________________
•	 Other ethnic group (please state) ___________________
5. Please list any general health problems you have (e.g. blood pressure or diabetes)
__________________________________________________________________
__________________________________________________________________
_____________________________________________________
6. Do you take any tablets or medicines? If so, please list the names below ________
__________________________________________________________________
__________________________________________________________________
___________________________________________
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7. Do you take any nutritional supplements (e.g. vitamins)? If so, please provide the 
name or brand _____________________________________________________
__________________________________________________________________
___
8. Do you smoke? ________________________
9. If so, how many cigarettes per day__________
10. If you don’t smoke at the moment but you have done previously, please give deta
11. ils________________________________________________________________
_____________________________________________________
11. Please give information about any previous visits to an eye clinic or eye             
specialist
__________________________________________________________________
__________________________________________________________________
______________________________________________________
12. Are you a contact lens wearer?____________________
a. If so, what type of lenses do you wear?__________________________
_________________________________________________________
__________________
b. How many days per week do you wear your lens-
es?______________________________________________
c. How many hours per day do you wear your lens-
es?______________________________________________
THANK YOU FOR YOUR TIME.
Sheeraz Janjua
janjuasa@aston.ac.uk
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Appendix 5
24-hour Food Recall Questionnaire
Food to be described as accurately as possible using visual props:
For example: 
One small or large bowl of Wheatabix with skimmed milk
Two slices of toast thinly or thickly spread with butter
Brown, White or Wholemeal bread
Skimmed or semi-skimmed milk
Large, medium or small apple
Accurate estimates of the food and drink consumed using visual props:
For example:
One small cup of coffee or one large mug of tea
One or two biscuits
One packet of crisps
Please ask the participant to recall all the food and drinks they consumed yesterday from 
waking to sleeping. If yesterday was a weekday, please also ask the participant to recall all 
the foods and drinks consumed during one preceding weekend day. If the previous day was 
a Sunday, please ask the participant to recall all the food and drinks they consumed the 
preceding Friday.
Remember to include all foods and drinks consumed at home and at other places such as 
at work and in restaurants.
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Study Number
Patient Identification Number
24 Hour Food Recall Questionnaire: weekday
Breakfast: Evening meal:
Lunch: In between snacks:
Study Number:
Patient Identification Number
87
24 Hour Food Recall Questionnaire: weekend day (please specify)
Breakfast: Evening meal:
Lunch: In between snacks:
THANK YOU FOR YOUR TIME.
Sheeraz Janjua
janjuasa@aston.ac.uk
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Appendix 6
OSDI Questionnaire
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Appendix 7
Clinical data collection form
Please do not evaluate the tear film until 10 minutes after the subject has arrived in order to 
allow the effect of external conditions on the tear film to settle
•	 Data can either be entered directly into the Bristol Online Survey (see link on INDES 
website) or into the INDES spreadsheet (which can be downloaded from the INDES 
website).
Date:________________                          Study loca-
tion:_________________________
Subject unique identification code:_______________  
(Created by using three letters of the mother’s maiden name followed by the last 
three digits in the phone number)
Chosen eye: R    L   (Right eye unless affected by pathology other than dry eye)   
                                                  
For all participants:
Vision in chosen eye using a standard LogMAR chart (standard viewing conditions)
Vision: ___________________
For distance spectacle/contact lens wearers:
Visual acuity in chosen eye using a standard LogMAR chart (standard viewing condi-
tions)
VA: ______________________ 
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Non-invasive tests: 
Manual Keratometry (three readings, plus an average, allowing one minute between 
readings). 
1st_______________ 2nd______________ 3rd_______________ Ave_________
Central Tear Meniscus Height:__________(mm)
Invasive tests: 
Fluorescein tear break up time (FTBUT):_________(seconds).
Ocular surface fluorescein staining assessment using the Efron grading scale 
(http://eprints.qut.edu.au/11857/):
Cornea: ______________ Bulbar conjunctiva: ______________
 
